Term	Overlap	P.value	Adjusted.P.value	Old.P.value	Old.Adjusted.P.value	Odds.Ratio	Combined.Score	Genes
Primary sclerosing cholangitis	10/36	1.66301409209909e-05	0.0158152640158624	0	0	6.65984474241355	73.2868881472548	BCL2L11;BCL2A1;SLCO3A1;CLEC16A;HLA-B;TNFRSF14;PSMG1;UBASH3A;STRN4;HLA-DRB1
Sum eosinophil basophil counts	21/173	0.000552748489902003	0.229913151856428	0	0	2.40054143700307	18.0055190349178	IFITM2;GPX4;BCL2A1;NCF4;TCF7;CLEC16A;IKZF1;RUNX1;APBB1IP;SPRED2;DAP;RAD50;BCL2L11;AUH;INPP5D;ELMO1;ST20-MTHFS;RIN3;ATM;IL18R1;BPTF
QRS duration	10/55	0.000739843112050822	0.229913151856428	0	0	3.84403669724771	27.7119388778806	NFIA;FAF1;GOSR2;SAP30L;VTI1A;DLEC1;PRKCA;STRN;SENP2;CCDC141
Rheumatoid arthritis	21/182	0.00107266297456991	0.229913151856428	0	0	2.26526171575936	15.4889783373584	BLK;CEP57;PXK;FCRL3;IFNGR2;PDE2A;PTPN11;TRAF1;ARAP1;TYK2;RUNX1;ETV7;SPRED2;ELMO1;REL;CTLA4;TNFRSF14;ATM;UBASH3A;HLA-DRB1;CDK5RAP2
Eosinophil percentage of white cells	19/160	0.00129218049525972	0.229913151856428	0	0	2.33839825220934	15.553678679941	IFITM3;GPX4;BCL2A1;NCF4;HLA-B;CLEC16A;CDC7;RUNX1;APBB1IP;RAD50;BCL2L11;WNK1;GKAP1;INPP5D;ELMO1;ST20-MTHFS;ATM;IL18R1;BPTF
Eosinophil counts	22/199	0.00145055616313204	0.229913151856428	0	0	2.15876859218264	14.1092975429149	IFITM2;GPX4;BCL2A1;NCF4;HLA-B;CLEC16A;IKZF1;UNC13D;RUNX1;APBB1IP;RAD50;BCL2L11;AUH;WNK1;INPP5D;ELMO1;ST20-MTHFS;RIN3;ATM;IL18R1;BPTF;PELP1
Rheumatoid arthritis (ACPA-positive)	11/74	0.0022901927431928	0.311139042682336	0	0	3.02020202020202	18.3601683837354	BLK;SPRED2;PXK;FCRL3;ACTN1;REL;CTLA4;UBASH3A;TYK2;TRAF1;RUNX1
IgA nephropathy	7/36	0.00306304843991972	0.345636160335963	0	0	4.16749219169006	24.1228810763495	FCRL3;TNFSF13;HLA-B;HLA-A;ACCS;PSMB8;HLA-DRB1
Psoriasis vulgaris	8/46	0.00329517004599682	0.345636160335963	0	0	3.63639868903027	20.7831003548781	ZMIZ1;DDX58;CARM1;HLA-B;ELMO1;REL;TYK2;KLF4
Nasopharyngeal carcinoma	5/20	0.00386575597926629	0.345636160335963	0	0	5.74885844748858	31.9383466074453	CIITA;HLA-B;HLA-A;CLPTM1L;HLA-F
Eosinophil percentage of granulocytes	17/152	0.00424145915211344	0.345636160335963	0	0	2.18190212373038	11.9193994985369	IFITM3;GPX4;BCL2A1;NCF4;CLEC16A;IKZF1;RUNX1;APBB1IP;RAD50;BCL2L11;AUH;GKAP1;INPP5D;ELMO1;ST20-MTHFS;IL18R1;BPTF
Hematological parameters	4/13	0.0043613395625989	0.345636160335963	0	0	7.66058394160584	41.6350900959891	TFR2;AK3;PTPN11;BYSL
Celiac disease or Rheumatoid arthritis	4/14	0.00584283765962284	0.427426047253947	0	0	6.89416058394161	35.4534876037157	SPRED2;ELMO1;TRAF1;UBASH3A
Functional impairment in major depressive disorder, bipolar disorder and schizophrenia	3/8	0.00754134269347911	0.483423886691723	0	0	10.334548769371	50.5086089806034	FCGR3A;ZZEF1;CYB5D2
Dementia and core Alzheimer's disease neuropathologic changes	4/15	0.00762498243993254	0.483423886691723	0	0	6.26708692767087	30.5603542885765	SLCO3A1;SMOX;BIN1;ABCG1
Heart failure	4/17	0.0121797784352666	0.648010847873207	0	0	5.30235822571589	23.372679508537	RPUSD4;GNA15;BTG1;USP3
Survival in pancreatic cancer	5/27	0.0146418799378831	0.648010847873207	0	0	3.91822332918223	16.5500634956871	GTF2H1;HPS5;RUNX2;LGR4;B4GALT4
White matter hyperintensity burden	5/27	0.0146418799378831	0.648010847873207	0	0	3.91822332918223	16.5500634956871	ZDHHC20;FBF1;TRIM47;CDC73;UNC13D
Cold sores	3/10	0.0148778755954734	0.648010847873207	0	0	7.38103919781221	31.0585274329363	HLA-B;HLA-A;HLA-DRB1
Plantar warts	3/10	0.0148778755954734	0.648010847873207	0	0	7.38103919781221	31.0585274329363	HLA-B;HLA-A;HLA-DRB1
Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)	4/18	0.0149907872273507	0.648010847873207	0	0	4.92335766423358	20.6796749633386	NFIA;FTH1;RUNX1;BEST1
Response to fenofibrate (adiponectin levels)	4/18	0.0149907872273507	0.648010847873207	0	0	4.92335766423358	20.6796749633386	ZBP1;OAS1;OAS2;OAS3
Systemic lupus erythematosus	30/365	0.0186779881874046	0.701510335108587	0	0	1.55377319012415	6.18465364563595	BLK;PXK;CIITA;NCF2;TNKS;TCF7;ICA1;CLEC16A;MTMR9;CREBL2;IKZF1;PPCDC;SPRED2;FCGR3A;RASSF2;SLC15A4;LYN;RABGAP1L;ZNF184;CMC1;HLA-B;ELP3;HLA-A;TYK2;LRRC63;ETV7;BIN1;UHRF1BP1;HLA-DRB1;SSBP4
Rheumatoid arthritis (ACPA-negative)	3/11	0.019632520996019	0.701510335108587	0	0	6.45806745670009	25.3838723395137	RNASEH2B;HLA-B;HLA-DRB1
Feeling fed-up	5/29	0.0196796620188045	0.701510335108587	0	0	3.59132420091324	14.1073304109553	NEK9;KIAA1109;ACBD4;ACTN1;TCF4
Chronic lymphocytic leukemia	9/74	0.0198767167705957	0.701510335108587	0	0	2.39039695409998	9.36606827066099	GRAMD1B;BCL2L11;CASP10;RFX7;OAS3;CLPTM1L;TSPAN32;STRN4;HLA-DRB1
Alzheimer's disease (late onset)	8/64	0.0235447717211751	0.701510335108587	0	0	2.46520146520147	9.24167418784538	BIN1;INPP5D;RIN3;ATM;SORL1;CD33;HLA-DRB1;PICALM
Itch intensity from mosquito bite	8/64	0.0235447717211751	0.701510335108587	0	0	2.46520146520147	9.24167418784538	KIAA1109;RAD50;IRF1;MAPKAP1;HLA-B;IKZF1;FBXO11;RUNX2
Peripheral arterial disease (traffic-related air pollution interaction)	3/12	0.025124836494471	0.701510335108587	0	0	5.74020054694622	21.1463157271395	WWOX;NSMCE1;UTRN
Polymyositis	3/12	0.025124836494471	0.701510335108587	0	0	5.74020054694622	21.1463157271395	BLK;MMAB;IL18R1
Platelet distribution width	16/170	0.025363174581478	0.701510335108587	0	0	1.79671251257967	6.60194282677475	ANKRD28;TPM4;RNPEPL1;BRF1;ACTN1;SWAP70;DOCK8;TPM1;FAM107B;CLN3;ZMIZ1;ELMO1;EPC1;TLK1;SNX9;SSBP3
Celiac disease	13/130	0.026835506454272	0.701510335108587	0	0	1.91996320147194	6.9464833110559	CIITA;CLEC16A;KIAA1109;ARHGAP31;NFIA;ZMIZ1;ELMO1;REL;CTLA4;TNFRSF14;UBASH3A;IL18R1;CCR2
Amyloid A serum levels	2/5	0.027039444032211	0.701510335108587	0	0	11.4735883424408	41.4249155771303	GTF2H1;HPS5
Extraversion	2/5	0.027039444032211	0.701510335108587	0	0	11.4735883424408	41.4249155771303	GBE1;MTMR9
Type 1 diabetes	10/91	0.0276864226960742	0.701510335108587	0	0	2.13149847094801	7.6452867263225	PSMB1;CLEC16A;CTLA4;PTPN11;IKZF1;UBASH3A;TYK2;DEXI;PGM1;HLA-DRB1
Atopic dermatitis	8/67	0.0300839021270792	0.701510335108587	0	0	2.33947972931024	8.19698734196025	RAD50;NCF4;HLA-B;CLEC16A;DEXI;RNF111;IL18R1;HLA-DRB1
Gut microbiota (bacterial taxa)	8/67	0.0300839021270792	0.701510335108587	0	0	2.33947972931024	8.19698734196025	TGS1;KDM8;NSMCE1;BNIP2;DLEC1;ACAA1;NAPG;MYD88
Platelet count	29/366	0.0313271737427957	0.701510335108587	0	0	1.49151213403264	5.16550831470388	IFITM2;SERPINA1;RNPEPL1;DOCK8;AK3;IRS2;ASAP1;SPINT2;RIC8A;PIEZO1;CD33;ABCC4;BRF1;TPM4;ACTN1;TPM1;HLA-B;PTPN11;TYK2;ARHGAP25;RUNX1;SIRT3;ETV7;TFR2;IRF1;NHP2;UHRF1BP1;RCOR1;PICALM
Airway responsiveness in chronic obstructive pulmonary disease	3/13	0.0313538973973267	0.701510335108587	0	0	5.16590701914312	17.8865227375313	RPTOR;ABCC4;PDSS2
Objective response to lithium treatment	3/13	0.0313538973973267	0.701510335108587	0	0	5.16590701914312	17.8865227375313	SESTD1;TCF3;CCDC141
Neutrophil percentage of granulocytes	14/148	0.0336275056437223	0.701510335108587	0	0	1.80536543800335	6.12454143830009	IFITM3;GPX4;BCL2A1;NCF4;CLEC16A;RUNX1;APBB1IP;BCL2L11;GKAP1;INPP5D;ELMO1;ST20-MTHFS;IL18R1;BPTF
Myositis	3/14	0.0383114707728895	0.701510335108587	0	0	4.69603049639513	15.3184793250555	DDX39B;HLA-B;HLA-DRB1
Neurofibrillary tangles	3/14	0.0383114707728895	0.701510335108587	0	0	4.69603049639513	15.3184793250555	BIN1;RASSF5;HLA-DRB1
Shingles	3/14	0.0383114707728895	0.701510335108587	0	0	4.69603049639513	15.3184793250555	HLA-B;HLA-A;HLA-DRB1
Asperger disorder	2/6	0.0390957389702998	0.701510335108587	0	0	8.60473588342441	27.8943319540071	SLTM;RNF111
Blood pressure measurement (high sodium and potassium intervention)	2/6	0.0390957389702998	0.701510335108587	0	0	8.60473588342441	27.8943319540071	ARL4C;IRAK1BP1
Blood pressure measurement (high sodium intervention)	2/6	0.0390957389702998	0.701510335108587	0	0	8.60473588342441	27.8943319540071	IRAK1BP1;KCNQ1
Erectile dysfunction in type 1 diabetes	2/6	0.0390957389702998	0.701510335108587	0	0	8.60473588342441	27.8943319540071	ALCAM;PHACTR2
Feeling lonely	2/6	0.0390957389702998	0.701510335108587	0	0	8.60473588342441	27.8943319540071	TCF4;DDB2
Hip shape (DXA scan)	2/6	0.0390957389702998	0.701510335108587	0	0	8.60473588342441	27.8943319540071	WWOX;RUNX2
Myasthenia gravis	2/6	0.0390957389702998	0.701510335108587	0	0	8.60473588342441	27.8943319540071	CTLA4;HLA-DRB1
Sporadic pituitary adenoma	2/6	0.0390957389702998	0.701510335108587	0	0	8.60473588342441	27.8943319540071	CDK8;RNF6
Strep throat	2/6	0.0390957389702998	0.701510335108587	0	0	8.60473588342441	27.8943319540071	HLA-B;HLA-DRB1
Immature fraction of reticulocytes	12/125	0.042562860344628	0.739366404277094	0	0	1.83371290994274	5.78861582352491	APBB1IP;DNMT1;BCL2L11;TFR2;SMOX;RP11-673E1.1;STRN;IKZF1;BAZ1A;WIPI2;RCOR1;HK1
Inflammatory bowel disease	50/709	0.0427604124450475	0.739366404277094	0	0	1.31808656694848	4.15479674869066	NCF4;LST1;IKZF1;APEH;SPRED2;KIAA1109;FCGR3A;AUH;ABHD16A;ZMIZ1;RASSF5;CTLA4;PHACTR2;PDE4A;CCNL2;CCR2;GPX1;GPX4;IFNGR2;SLC2A13;HLA-B;FOS;TYK2;PRKAB1;SCAMP3;DDX39B;DDAH2;IRF1;LTB;SLC35D1;CUL2;RNF5;BAG6;CLN3;NLRP7;PMVK;DVL1;TNFRSF14;FYN;UBQLN4;HSPA1L;SLC16A10;ASXL1;EFNA3;DAP;REL;PSMG1;HLA-DRB1;GPR18;IL18R1
Prostate cancer (advanced)	3/15	0.0459831041834101	0.745582539110911	0	0	4.30446672743847	13.2555245797945	BCL2L11;UHRF1BP1;TCF4
Multiple sclerosis	20/244	0.0490700974354066	0.745582539110911	0	0	1.54398148148148	4.6543405801896	WWOX;FCRL3;IFNGR2;NCF4;TCF7;HLA-B;CLEC16A;CXCR4;ASAP1;IKZF1;BCL10;TYK2;IFI30;ZMIZ1;TBX21;VTI1A;ELMO1;CTLA4;TNFRSF14;HLA-DRB1
Small cell lung carcinoma	8/74	0.0499272054027013	0.745582539110911	0	0	2.09057609057609	6.26585213551952	BAG6;NRP1;BTN3A1;DST;SPNS3;HLA-B;HLA-DRB1;HLA-E
Monocyte percentage of white cells	15/171	0.050214715624307	0.745582539110911	0	0	1.66111308046792	4.96913199922251	IFITM2;SIGLEC9;BCL2A1;ARRDC2;HLA-B;IKZF1;APBB1IP;AKAP13;BCL2L11;DDX39B;FAM177A1;GCNT2;KCNN4;CCR2;SLC25A24
Periodontitis (CDC/AAP)	4/26	0.0518347257966999	0.745582539110911	0	0	3.13171864631719	9.2689319316833	BLK;ETAA1;MFSD1;PARP15
Acute lymphoblastic leukemia (B-cell precursor)	2/7	0.0527687944139587	0.745582539110911	0	0	6.88342440801457	20.2499007560846	PIP4K2A;IKZF1
Beta-2 microglubulin plasma levels	2/7	0.0527687944139587	0.745582539110911	0	0	6.88342440801457	20.2499007560846	HLA-B;HLA-A
Decline in glucose metabolism in posterior cingulate cortex	2/7	0.0527687944139587	0.745582539110911	0	0	6.88342440801457	20.2499007560846	TBC1D8;CDH23
Multiple sclerosis and HDL levels (pleiotropy)	2/7	0.0527687944139587	0.745582539110911	0	0	6.88342440801457	20.2499007560846	UBASH3B;CMC1
Neuromyelitis optica	2/7	0.0527687944139587	0.745582539110911	0	0	6.88342440801457	20.2499007560846	HLA-B;HLA-DRB1
Neuromyelitis optica (AQP4-IgG-positive)	2/7	0.0527687944139587	0.745582539110911	0	0	6.88342440801457	20.2499007560846	HLA-B;HLA-DRB1
Systolic blood pressure response to hydrochlorothiazide in hypertension	3/16	0.0543491014253808	0.745582539110911	0	0	3.9731435383213	11.5710939908463	ETAA1;LSM6;ZDHHC2
Uterine fibroids	6/50	0.0552790041203903	0.745582539110911	0	0	2.35034070134619	6.8050874237225	RIC8A;STN1;EDEM1;ITPR1;ATM;SIRT3
Acute lymphoblastic leukemia (childhood)	5/38	0.0556375761174778	0.745582539110911	0	0	2.61062681610627	7.54183061062184	SLCO3A1;INTS10;TBXAS1;PIP4K2A;IKZF1
Anti-saccade response	5/38	0.0556375761174778	0.745582539110911	0	0	2.61062681610627	7.54183061062184	HNRNPL;USP12;DIP2A;MB21D2;ZZEF1
Granulocyte percentage of myeloid white cells	14/159	0.0556638909325706	0.745582539110911	0	0	1.66742871658094	4.81624048957775	IFITM2;SIGLEC9;BCL2A1;ARRDC2;DOCK8;LST1;FOXJ2;IKZF1;AKAP13;SPRED2;BCL2L11;KCNN4;CCR2;SLC25A24
Asthma (moderate or severe)	4/27	0.0583030535490942	0.77008616562762	0	0	2.99539828625833	8.51322389718097	RPS26;KIAA1109;RAD50;CLEC16A
Metabolite levels (small molecules and protein measures)	5/39	0.0610561706727874	0.795402990545491	0	0	2.53370937416062	7.08415261528058	SERPINA1;ATMIN;LMAN2;DVL2;SLC16A10
Photic sneeze reflex	7/65	0.0653385397048073	0.806503079807381	0	0	2.08054390005363	5.67608415581166	SLC35B3;ETAA1;STIM2;CDC73;TRIM44;CBR4;CDK5RAP2
Arthritis (juvenile idiopathic)	2/8	0.0678446334222823	0.806503079807381	0	0	5.73588342440801	15.4325950551638	CXCR4;HLA-DRB1
Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction)	2/8	0.0678446334222823	0.806503079807381	0	0	5.73588342440801	15.4325950551638	SLC12A2;TNIK
Estradiol levels	2/8	0.0678446334222823	0.806503079807381	0	0	5.73588342440801	15.4325950551638	FTH1;BEST1
Metabolite levels (HVA-5-HIAA Factor score)	2/8	0.0678446334222823	0.806503079807381	0	0	5.73588342440801	15.4325950551638	RAB10;VGLL4
Pneumonia	2/8	0.0678446334222823	0.806503079807381	0	0	5.73588342440801	15.4325950551638	HLA-B;HLA-DRB1
Response to treatment for acute lymphoblastic leukemia	2/8	0.0678446334222823	0.806503079807381	0	0	5.73588342440801	15.4325950551638	MAML2;ELMO1
Vitiligo	11/121	0.0695449624897562	0.808137604828943	0	0	1.72543617998163	4.59963635407837	RPS26;PTPN1;BCL2L11;IRF3;ZMIZ1;HLA-B;CDH23;CTLA4;UBASH3A;HLA-A;HLA-DRB1
Colorectal or endometrial cancer	4/29	0.0724607706278782	0.808137604828943	0	0	2.75547445255474	7.2323212356105	SCAF8;ARL5B;KLF4;FBP1
JT interval (sulfonylurea treatment interaction)	3/18	0.0730643268667773	0.808137604828943	0	0	3.44302643573382	9.00838613544768	NFIA;TM2D1;FARS2
Renal cell carcinoma	3/18	0.0730643268667773	0.808137604828943	0	0	3.44302643573382	9.00838613544768	FAF1;ITPR2;ATM
Mosquito bite size	9/95	0.0774701264629576	0.808137604828943	0	0	1.80468100526507	4.6161265570874	NCOR2;SLC25A37;KIAA1109;DDX39B;TNKS;ACTN1;KCNQ1;IKZF1;RUNX2
Gallstone disease	4/30	0.0801353167633919	0.808137604828943	0	0	2.6493542953397	6.68707254273645	MLLT10;SERPINA1;KDELR3;TTC39B
Alcohol dependence symptom count	3/19	0.0833553384536852	0.808137604828943	0	0	3.22766636280766	8.01959741850684	PTPN11;ARAP1;BPTF
Acute lymphoblastic leukemia in childhood (B cell precursor)	2/9	0.0841278894616881	0.808137604828943	0	0	4.91621129326047	12.1696737206609	PIP4K2A;IKZF1
Advanced glycation end-product levels	2/9	0.0841278894616881	0.808137604828943	0	0	4.91621129326047	12.1696737206609	FBXO33;RNF5
Amino acid levels	2/9	0.0841278894616881	0.808137604828943	0	0	4.91621129326047	12.1696737206609	SLC16A10;PSPH
Asparaginase hypersensitivity in acute lymphoblastic leukemia	2/9	0.0841278894616881	0.808137604828943	0	0	4.91621129326047	12.1696737206609	DERL2;HLA-DRB1
Clozapine-induced cytotoxicity	2/9	0.0841278894616881	0.808137604828943	0	0	4.91621129326047	12.1696737206609	WWOX;B4GALT4
Coenzyme Q10 levels	2/9	0.0841278894616881	0.808137604828943	0	0	4.91621129326047	12.1696737206609	BCR;TTC39B
Disc degeneration (lumbar)	2/9	0.0841278894616881	0.808137604828943	0	0	4.91621129326047	12.1696737206609	RAB40C;ARL8B
Economic and political preferences	2/9	0.0841278894616881	0.808137604828943	0	0	4.91621129326047	12.1696737206609	ACBD4;DCBLD1
Giant cell arteritis	2/9	0.0841278894616881	0.808137604828943	0	0	4.91621129326047	12.1696737206609	HLA-B;HLA-DRB1
Optic nerve measurement (cup area)	2/9	0.0841278894616881	0.808137604828943	0	0	4.91621129326047	12.1696737206609	RFTN1;PDE2A
Prostate-specific antigen levels (conditioned on lead SNPs)	2/9	0.0841278894616881	0.808137604828943	0	0	4.91621129326047	12.1696737206609	SLC25A37;WDR11
White matter lesion progression	2/9	0.0841278894616881	0.808137604828943	0	0	4.91621129326047	12.1696737206609	IRS2;CNNM2
Psoriasis	11/127	0.0907594423513501	0.845000422471102	0	0	1.63566701497736	3.92485294895912	RPS26;AKAP13;ZMIZ1;DDX58;CARM1;HLA-B;ELMO1;REL;TRIM47;TYK2;KLF4
Allergic disease (asthma, hay fever or eczema)	14/172	0.0924000332745393	0.845000422471102	0	0	1.52917453434972	3.64192479648097	CEP19;HLA-B;CLEC16A;IKZF1;TRAF1;RUNX1;RAD50;BCL2L11;INPP5D;LMAN2;CAMK4;TNFRSF14;RCOR1;IL18R1
Feeling guilty	3/20	0.0942255901450999	0.845000422471102	0	0	3.03764276904928	7.17510504003549	ACBD4;GOSR2;PRKCA
High density lipoprotein cholesterol levels	7/71	0.094719469957905	0.845000422471102	0	0	1.88489249771272	4.44238193633175	VAC14;FAM222A;RILPL2;PABPC4;IKZF1;HLA-DRB1;HERPUD1
Pediatric autoimmune diseases	5/45	0.0995240657496279	0.845000422471102	0	0	2.15296803652968	4.96766328034244	ZMIZ1;FNBP1;PSMG1;TYK2;IL18R1
Tuberculosis	7/72	0.100227766233079	0.845000422471102	0	0	1.85579562249279	4.26890526661352	LRPAP1;GRAMD2B;CNOT6L;HLA-B;ASAP1;KIAA2013;HLA-DRB1
Epstein-Barr virus immune response (EBNA-1)	2/10	0.10144040957528	0.845000422471102	0	0	4.30145719489982	9.84295460337859	HLA-B;HLA-DRB1
Nodular sclerosis Hodgkin lymphoma	2/10	0.10144040957528	0.845000422471102	0	0	4.30145719489982	9.84295460337859	CLEC16A;HLA-DRB1
Panic disorder	2/10	0.10144040957528	0.845000422471102	0	0	4.30145719489982	9.84295460337859	USP25;SMOX
Hemoglobin	4/33	0.105422318462378	0.845000422471102	0	0	2.37490561288699	5.34301732321116	PRKCE;MICALL2;ATXN10;HK1
Alzheimer's disease in APOE e4+ carriers	3/21	0.105640504823328	0.845000422471102	0	0	2.86873290793072	6.44808943504236	BIN1;PEX6;PICALM
Gut microbiota (beta diversity)	3/21	0.105640504823328	0.845000422471102	0	0	2.86873290793072	6.44808943504236	PLSCR1;CLEC16A;DEXI
Heart rate response to exercise	3/21	0.105640504823328	0.845000422471102	0	0	2.86873290793072	6.44808943504236	TCF4;CCDC141;HLA-DRB1
Obesity (early onset extreme)	3/21	0.105640504823328	0.845000422471102	0	0	2.86873290793072	6.44808943504236	TNKS;TCF4;FARS2
Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid)	3/21	0.105640504823328	0.845000422471102	0	0	2.86873290793072	6.44808943504236	STIM2;FTH1;BEST1
Systemic lupus erythematosus and Systemic sclerosis	3/21	0.105640504823328	0.845000422471102	0	0	2.86873290793072	6.44808943504236	BLK;PXK;UHRF1BP1
Cadmium levels	5/46	0.106892418089805	0.845000422471102	0	0	2.10034525002784	4.69622997204308	IRAK1BP1;GBE1;SORL1;TAF3;MTURN
Erectile dysfunction	5/46	0.106892418089805	0.845000422471102	0	0	2.10034525002784	4.69622997204308	NFIA;PAM16;REL;AATF;CCT4
Late-onset Alzheimer's disease	5/46	0.106892418089805	0.845000422471102	0	0	2.10034525002784	4.69622997204308	IRAK1BP1;SESTD1;RASSF5;TBXAS1;TFEB
Mean corpuscular volume	26/365	0.107177673880862	0.845000422471102	0	0	1.32547255318798	2.96013453403691	ZFAND4;IRS2;IKZF1;HK1;AKAP13;CHAF1A;ALOX5;TBX21;PIEZO1;KCNN4;CNNM2;FBXO7;ATMIN;SWAP70;GLRX5;AXIN1;SLC16A10;BAZ1A;WIPI2;PTGR2;QKI;BYSL;RAB10;KAT2B;SLC25A37;TFR2
Albumin-globulin ratio	6/60	0.110954142678779	0.845000422471102	0	0	1.91407678244973	4.20836250781996	BLK;TNFSF13;HLA-B;CXCR4;IKZF1;HLA-F
Ankylosing spondylitis	5/47	0.114519662518229	0.845000422471102	0	0	2.05022831050228	4.44286267950095	ZMIZ1;TBX21;HLA-B;PSMG1;TYK2
Immune response to smallpox vaccine (IL-6)	5/47	0.114519662518229	0.845000422471102	0	0	2.05022831050228	4.44286267950095	BLK;BCR;RAB10;SNX18;RUNX1
Hemoglobin levels	4/34	0.114565444927662	0.845000422471102	0	0	2.2956204379562	4.97371201130975	TFR2;PRKCE;IKZF1;HK1
Mean corpuscular hemoglobin	24/336	0.11527461535283	0.845000422471102	0	0	1.328853302831	2.87090522192439	RNPEPL1;SMOX;GLRX5;HLA-B;AXIN1;AK3;SLC16A10;IRS2;IKZF1;RRP1B;WIPI2;QKI;BYSL;HK1;RAB10;KAT2B;SLC25A37;CHAF1A;TFR2;ALOX5;TBX21;EHBP1L1;CNNM2;FBXO7
Regular attendance at a religious group	8/89	0.116150318291106	0.845000422471102	0	0	1.7020757020757	3.66434785191369	UBA7;NFIA;TNKS;AMZ2;TCF4;CD47;APEH;BPTF
Heart rate response to recovery post exercise (10 sec)	3/22	0.117564249616006	0.845000422471102	0	0	2.71760303219306	5.8177638302426	TRIP6;CCDC141;MED13L
Cutaneous lupus erythematosus	2/11	0.119619954629638	0.845000422471102	0	0	3.82331511839709	8.11856345785995	TRIM39;RPP21
Inflammatory bowel disease (early onset)	2/11	0.119619954629638	0.845000422471102	0	0	3.82331511839709	8.11856345785995	CLN3;ZMIZ1
Mortality in heart failure	2/11	0.119619954629638	0.845000422471102	0	0	3.82331511839709	8.11856345785995	CMTM7;IFRD1
Neuritic plaque	2/11	0.119619954629638	0.845000422471102	0	0	3.82331511839709	8.11856345785995	SLCO3A1;ABCG1
Optic nerve measurement (cup-to-disc ratio)	2/11	0.119619954629638	0.845000422471102	0	0	3.82331511839709	8.11856345785995	RFTN1;CDC7
QRS complex (12-leadsum)	2/11	0.119619954629638	0.845000422471102	0	0	3.82331511839709	8.11856345785995	USP25;PRKCA
Systemic lupus erythematosus or rheumatoid arthritis	2/11	0.119619954629638	0.845000422471102	0	0	3.82331511839709	8.11856345785995	BLK;TYK2
ALT levels after remission induction therapy in actute lymphoblastic leukemia (ALL)	5/48	0.122398906291454	0.845000422471102	0	0	2.00244239141977	4.20606985846796	HDAC4;CAST;TLE4;PDCD6IP;FNBP1
Periodontitis (Mean PAL)	4/35	0.124042923935299	0.845000422471102	0	0	2.2214504356016	4.63645054396286	PDCD6IP;ACTN1;MTHFS;ETS2
Attention function in attention deficit hyperactive disorder	3/23	0.129960159043375	0.845000422471102	0	0	2.58158614402917	5.2677971188024	DST;CAAP1;ZNF622
Metabolite levels (Pyroglutamine)	3/23	0.129960159043375	0.845000422471102	0	0	2.58158614402917	5.2677971188024	DAP;ICA1;MYO5A
Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)	3/23	0.129960159043375	0.845000422471102	0	0	2.58158614402917	5.2677971188024	ALCAM;FTH1;BEST1
Response to fenofibrate (HDL cholesterol levels)	3/23	0.129960159043375	0.845000422471102	0	0	2.58158614402917	5.2677971188024	WWOX;CREBL2;CDC7
Ulcerative colitis	31/456	0.131275251842947	0.845000422471102	0	0	1.26060639410114	2.55960959964862	GRAMD1B;CIITA;MAML2;SLC35D1;UBA7;LST1;USP12;APEH;RNF5;BAG6;FCGR3A;ABHD16A;DVL1;CTLA4;TNFRSF14;FYN;CCNL2;CCR2;GPX1;HSPA1L;HLA-B;SLC16A10;PRKAB1;DAP;DDX39B;DDAH2;IRF1;REL;PSMG1;LTB;HLA-DRB1
Beard thickness	4/36	0.133839865333541	0.845000422471102	0	0	2.15191605839416	4.32774254778088	SLC12A2;EDAR;PREP;SRM
Total body bone mineral density	4/36	0.133839865333541	0.845000422471102	0	0	2.15191605839416	4.32774254778088	DGKD;APC;ARHGAP25;MED13L
Extremely high intelligence	7/78	0.136793385781575	0.845000422471102	0	0	1.69842660721879	3.37865223717659	SMARCAL1;PREX1;CLN3;GPX1;UBA7;APEH;AVL9
Bipolar disorder (body mass index interaction)	2/12	0.138518990261666	0.845000422471102	0	0	3.4408014571949	6.80159687917866	WWOX;CDH23
Food addiction	2/12	0.138518990261666	0.845000422471102	0	0	3.4408014571949	6.80159687917866	PRKCA;OSGEP
Metabolite levels (HVA)	2/12	0.138518990261666	0.845000422471102	0	0	3.4408014571949	6.80159687917866	RAB10;VGLL4
HDL cholesterol levels	8/93	0.139268339397801	0.845000422471102	0	0	1.62163326869209	3.19681113497955	PABPC4;COPB1;ALOX5;PMVK;TMEM176A;IKZF1;HERPUD1;TTC39B
Lung adenocarcinoma	10/123	0.13980288102854	0.845000422471102	0	0	1.52529024924901	3.00104187953505	SPRED2;ETAA1;TLE1;ZNF184;HLA-A;CLPTM1L;HLA-DRB1;GALK2;DCBLD1;BPTF
Diabetic kidney disease	3/24	0.142791105817524	0.845000422471102	0	0	2.45852324521422	4.78520207248347	SCAF8;ITPR1;MED13L
Psoriatic arthritis	3/24	0.142791105817524	0.845000422471102	0	0	2.45852324521422	4.78520207248347	HLA-B;REL;TYK2
Height	35/527	0.143316470394864	0.845000422471102	0	0	1.22958891560747	2.38872240392352	CLIC4;SERPINA1;MAML2;PLAG1;PELI2;PPP2R2A;SMPD2;RAB40C;ZMIZ1;RSBN1L;TGS1;GATAD1;PDE6D;LTA4H;LYN;SLC12A2;MAP2K2;ACBD4;CAMLG;IGFBP4;SMOX;TMEM176A;HLA-B;PRKCA;LRRC37B;DCBLD1;RUNX2;PDIA4;ETV6;BCR;DAP;LYRM4;KCNQ1;PPIF;VGLL4
Colorectal cancer	10/124	0.145074078271894	0.845000422471102	0	0	1.5118300338001	2.91860418138446	PREX1;WWOX;SLC25A28;ZMIZ1;VTI1A;TFEB;CXCR4;DCBLD1;MED13L;ETV6
Glycated hemoglobin levels	6/66	0.154212093589429	0.845000422471102	0	0	1.72212065813528	3.21937781021627	G6PC3;KCNQ1;TMC8;ARAP1;KLF4;HK1
Periodontal disease-related phenotypes	4/38	0.154329310228659	0.845000422471102	0	0	2.02511807642765	3.78427047308615	NIN;MAP4K5;SLC15A4;SOS2
Heart rate response to recovery post exercise (20 sec)	3/25	0.156019823946024	0.845000422471102	0	0	2.34664788265518	4.35953720716314	TRIP6;CCDC141;MED13L
Monobrow thickness	3/25	0.156019823946024	0.845000422471102	0	0	2.34664788265518	4.35953720716314	EDAR;RFX3;ANKRA2
Bipolar disorder (inflammation and infection response interaction)	2/13	0.158003562510561	0.845000422471102	0	0	3.12783573439311	5.77128762878893	AUH;RNF38
Eye morphology	2/13	0.158003562510561	0.845000422471102	0	0	3.12783573439311	5.77128762878893	PSMG1;ETS2
IgG galactosylation phenotypes (multivariate analysis)	2/13	0.158003562510561	0.845000422471102	0	0	3.12783573439311	5.77128762878893	HLA-B;IKZF1
QT interval (sulfonylurea treatment interaction)	2/13	0.158003562510561	0.845000422471102	0	0	3.12783573439311	5.77128762878893	NFIA;TM2D1
Response to taxane treatment (placlitaxel)	2/13	0.158003562510561	0.845000422471102	0	0	3.12783573439311	5.77128762878893	ZNF254;TSPAN15
Type 2 diabetes nephropathy	2/13	0.158003562510561	0.845000422471102	0	0	3.12783573439311	5.77128762878893	AUH;ELMO1
Lymphocyte counts	13/174	0.162620119053589	0.845000422471102	0	0	1.39198432062717	2.52831451265311	TLE4;SLC35D1;ARRDC2;CMC1;MINK1;CLEC16A;TRAF1;TYK2;RILPL2;FAM177A1;DIP2A;TNIK;HLA-DRB1
Total cholesterol levels	14/190	0.163469549773687	0.845000422471102	0	0	1.37146325129751	2.48389624408586	MYLIP;LRPAP1;SERPINA1;PRKCE;IRF2BP2;RPL23A;IKZF1;TRAM2;HERPUD1;TTC39B;SPRED2;UBASH3B;ALOX5;VIM
HDL cholesterol	17/238	0.163636168601626	0.845000422471102	0	0	1.32672775055047	2.40152290290605	AGPAT5;UVRAG;MMAB;PABPC4;COPB1;TMEM176A;IKZF1;RUNX1;HERPUD1;LILRA5;TTC39B;UBASH3B;ALOX5;OAS3;PMVK;MAP3K5;BPTF
Red blood cell traits	7/82	0.1643118043296	0.845000422471102	0	0	1.60750228728271	2.90313210790769	TFR2;PRKCE;PIEZO1;IKZF1;KCTD17;FBXO7;HK1
Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)	4/39	0.164989100641988	0.845000422471102	0	0	1.96715328467153	3.5445660243959	ZNF184;HLA-B;RPP21;HLA-E
Hemoglobin concentration	10/128	0.167151592665577	0.845000422471102	0	0	1.46027056445343	2.61221104153036	UVRAG;NASP;TFR2;DDX58;PRKCE;AP3D1;PIEZO1;HLA-A;KCNN4;HK1
Aortic root size	3/26	0.169609188998468	0.845000422471102	0	0	2.24450081249257	3.98232436802225	GOSR2;USP3;TSR1
Lupus nephritis in systemic lupus erythematosus	3/26	0.169609188998468	0.845000422471102	0	0	2.24450081249257	3.98232436802225	NIN;PRPF18;MAP4K5
Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)	3/26	0.169609188998468	0.845000422471102	0	0	2.24450081249257	3.98232436802225	TLE4;FTH1;BEST1
Serum thyroid-stimulating hormone levels	3/26	0.169609188998468	0.845000422471102	0	0	2.24450081249257	3.98232436802225	LYN;WWOX;TGS1
Non-albumin protein levels	6/68	0.170074852133457	0.845000422471102	0	0	1.66639146075367	2.95204018843288	BLK;HLA-H;TNFSF13;HLA-B;CXCR4;IKZF1
Fibrinogen	4/40	0.175903134988104	0.845000422471102	0	0	1.91240875912409	3.32342564137013	LRPAP1;ACTN1;IRF1;PSMG1
Asthma exacerbations in inhaled corticosteroid treatment	2/14	0.177952252413854	0.845000422471102	0	0	2.86703096539162	4.94918356104947	MYLIP;DTNBP1
Hepatocellular carcinoma	2/14	0.177952252413854	0.845000422471102	0	0	2.86703096539162	4.94918356104947	UBE4B;HLA-DRB1
Right lateral prefrontal cortical growth	2/14	0.177952252413854	0.845000422471102	0	0	2.86703096539162	4.94918356104947	UXS1;PDE7A
Regular attendance at a gym or sports club	4/41	0.187054213211545	0.845000422471102	0	0	1.86062339711975	3.1190686726905	UBA7;TCF4;APEH;LEMD2
Reticulocyte fraction of red cells	13/180	0.192552583439956	0.845000422471102	0	0	1.34154322449857	2.21003952888728	DNMT1;INO80D;SMOX;SWAP70;VPS13A;TMC8;IRS2;BAZ1A;HK1;SLC25A37;BCL2L11;TFR2;PIEZO1
Loneliness (MTAG)	6/71	0.195062198822789	0.845000422471102	0	0	1.58922795668682	2.59749266069547	PHF2;PREX1;GBE1;AMZ2;TCF4;BPTF
Mean corpuscular hemoglobin concentration	10/133	0.196851309378743	0.845000422471102	0	0	1.40053703289326	2.27630209705126	RIC8A;SLC25A37;TFR2;SWAP70;EHBP1L1;AXIN1;PIEZO1;KCTD17;KCNN4;MYD88
Epilepsy and lamotrigine-induced maculopapular eruptions	3/28	0.197723484409923	0.845000422471102	0	0	2.06472196900638	3.34667845391783	COTL1;WDR89;PDE7A
Red blood cell count	17/246	0.197908207689688	0.845000422471102	0	0	1.2798308112271	2.07326442255237	PXK;DDX58;PRKCE;AP3D1;AXIN1;IKZF1;HLA-A;QKI;BYSL;HK1;SLC25A37;TFR2;LMAN2;MICALL2;PIEZO1;ATM;FBXO7
Blood trace element (Cu levels)	2/15	0.198255204445256	0.845000422471102	0	0	2.64635000700574	4.28232402296244	LRRC47;DFFB
Common carotid intima-media thickness in HIV negative individuals	2/15	0.198255204445256	0.845000422471102	0	0	2.64635000700574	4.28232402296244	CCDC126;DLEC1
Late-onset myasthenia gravis	2/15	0.198255204445256	0.845000422471102	0	0	2.64635000700574	4.28232402296244	HLA-A;HLA-DRB1
Response to taxane treatment (docetaxel)	2/15	0.198255204445256	0.845000422471102	0	0	2.64635000700574	4.28232402296244	ZNF254;SLC6A6
Mean platelet volume	19/281	0.20704308264403	0.845000422471102	0	0	1.25033366052072	1.96906093137865	DENND2D;BRD1;BRF1;TPM4;RNPEPL1;ACTN1;DOCK8;TPM1;HLA-B;ASAP1;ARAP1;ETV7;KIAA1109;NIN;DDX39B;ELMO1;SIDT1;ESYT2;RCOR1
Cognitive decline (age-related)	4/43	0.209997926661354	0.845000422471102	0	0	1.76501965188097	2.75459137154864	ARL4C;VTI1A;STRN;AZI2
Feeling worry	4/43	0.209997926661354	0.845000422471102	0	0	1.76501965188097	2.75459137154864	CEP57;GOSR2;TCF4;APEH
Melanoma	4/43	0.209997926661354	0.845000422471102	0	0	1.76501965188097	2.75459137154864	AFG3L1P;ATM;CLPTM1L;TMEM38B
Hodgkin's lymphoma	3/29	0.212176876845041	0.845000422471102	0	0	1.98520440361826	3.07773192352731	CLEC16A;REL;TCF3
Loneliness	8/104	0.213176153462839	0.845000422471102	0	0	1.43498168498168	2.21795998805659	PREX1;PHF2;GBE1;CAAP1;AMZ2;TCF4;AGAP3;BPTF
Manganese levels	5/58	0.213200783903357	0.845000422471102	0	0	1.62376152321875	2.50955738674802	CDK17;SERPINA1;AEBP2;WNK1;RABL6
B-cell malignancies (CLL, Hodgkin lymphoma or multiple myeloma) (pleiotropy)	2/16	0.218813223643163	0.845000422471102	0	0	2.45719489981785	3.73379800903198	GRAMD1B;BCL2L11
Cotinine glucuronidation	2/16	0.218813223643163	0.845000422471102	0	0	2.45719489981785	3.73379800903198	KLF4;FAM107B
Electroencephalogram traits	2/16	0.218813223643163	0.845000422471102	0	0	2.45719489981785	3.73379800903198	CD72;MSH2
Progressive supranuclear palsy	2/16	0.218813223643163	0.845000422471102	0	0	2.45719489981785	3.73379800903198	ASAP1;RUNX2
Allergic sensitization	4/44	0.221755630127767	0.845000422471102	0	0	1.72080291970803	2.59183768298831	KIAA1109;CAMK4;HLA-B;IL18R1
Gamma glutamyl transferase levels	5/59	0.223272321958054	0.845000422471102	0	0	1.59360730593607	2.38939595511187	CYFIP2;SPRED2;BHLHE40-AS1;MAP3K7CL;ITPR1
C-reactive protein levels	3/30	0.226848163032702	0.845000422471102	0	0	1.91157702825889	2.83577552889339	PABPC4;IRF1;PSMG1
Cerebrospinal fluid AB1-42 levels	5/60	0.233483066025444	0.845000422471102	0	0	1.5645496056455	2.27586539834093	ELMO1;TNIK;MAPRE2;RNF111;FRA10AC1
Lead levels	4/45	0.233680661568574	0.845000422471102	0	0	1.67874310129963	2.44055636782942	IVNS1ABP;BHLHE40-AS1;ITPR1;MLYCD
Diverticular disease	11/156	0.240288721940367	0.845000422471102	0	0	1.30651340996169	1.86297585467848	UPF2;SLC25A28;SLC35D1;AEBP2;MAPKAP1;EDEM1;IFNGR2;TBX21;TPM1;PIEZO1;UBASH3A
Cervical cancer	3/31	0.241703903593431	0.845000422471102	0	0	1.84320875113947	2.61743354800276	TBXAS1;HLA-B;HLA-DRB1
Response to antidepressants (symptom improvement)	3/31	0.241703903593431	0.845000422471102	0	0	1.84320875113947	2.61743354800276	ZNF639;TMED7-TICAM2;FEM1C
Crohn's disease	38/613	0.243655884556773	0.845000422471102	0	0	1.14034225824941	1.61016139655342	DGKD;SLC35D1;NCF4;CUL2;LST1;AK3;IKZF1;APEH;CLN3;KIAA1109;SLC25A28;ZMIZ1;INPP5D;EP300;PDE4A;UBQLN4;IFNAR2;HLA-H;GPX1;GPX4;IFNGR2;SLC2A13;HLA-B;FOS;HLA-A;TYK2;HLA-F;LEMD2;SCAMP3;NUDT22;EFNA3;DAP;IRF1;REL;LTB;GART;HLA-DRB1;IL18R1
Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	HDAC4
Appendicular lean mass	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	HSD17B11
Cannabis dependence	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	CHST11
Conotruncal heart defects (inherited effects)	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	FEM1C
Discordance in emotional problems in monozygotic twins	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	ZNF254
Entorhinal cortical thickness	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	ME2
GLP-1 levels in response to oral glucose tolerance test (fasting)	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	ZFAND2A
Glomerular filtration rate (cystatin C)	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	CST3
Iris color (a* coordinate)	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	HK1
Liver fibrosis in pediatric non-alcoholic fatty acid liver disease	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	ACTR5
Multiple sclerosis--Brain Glutamate Levels	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	SUMF1
Mumps	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	HLA-A
Neuritic plaques or neurofibrillary tangles (pleiotropy)	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	BIN1
Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy)	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	TRAPPC12
Normalized brain volume	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	BICD1
Optic disc parameters	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	CDC7
Parkinson's disease (motor and cognition)	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	LMNB1
Plasma homocysteine levels (post-methionine load test)	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	PSPH
Premature menopause in childhood cancer survivors	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	PRKCE
Response to antidepressants	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	UST
Response to antineoplastic agents	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	PPP2R5E
Response to methylphenidate treatment in ADHD (blood pressure)	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	MARK2
Rheumatoid arthritis (rheumatoid factor and/or anti-CCP seropositive)	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	HLA-DRB1
Spontaneous preterm birth (preterm birth)	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	SORL1
Suicide risk	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	PRKCE
Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	ETAA1
Yeast infection	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	HLA-DRB1
facial morphology traits (multivariate analysis)	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	RUNX2
middle facial morphology traits (quantitative measurement)	1/5	0.246389997709319	0.845000422471102	0	0	4.29845313921747	6.02144355608867	RUNX1
Inflammatory skin disease	7/93	0.250648438888148	0.845000422471102	0	0	1.40107236324177	1.93866938223235	RPS26;KIAA1109;RAD50;DDX58;ELMO1;PDE4A;SMARCA4
Tonsillectomy	5/62	0.254279599563858	0.845000422471102	0	0	1.50949291035809	2.06698008745593	SPRED2;LST1;HLA-B;IKZF1;HLA-DRB1
Hippocampal atrophy	3/32	0.256711793259136	0.845000422471102	0	0	1.7795555276145	2.41984183154224	ZBP1;TLE1;IKZF1
Autism spectrum disorder, ADHD, bipolar disorder, MDD, and schizophrenia (combined)	4/47	0.257963739384592	0.845000422471102	0	0	1.60049227635376	2.16856500141039	HDAC4;ZMIZ1;TCF4;CNNM2
Paclitaxel disposition in epithelial ovarian cancer	4/47	0.257963739384592	0.845000422471102	0	0	1.60049227635376	2.16856500141039	WWOX;PINK1;WNK1;IRS2
Primary biliary cirrhosis	4/47	0.257963739384592	0.845000422471102	0	0	1.60049227635376	2.16856500141039	CLEC16A;ELMO1;TYK2;HLA-DRB1
Cerebrospinal fluid levels of Alzheimer's disease-related proteins	2/18	0.260346014817999	0.845000422471102	0	0	2.14981785063752	2.89310384263371	ADAR;CCR2
Idiopathic pulmonary fibrosis	2/18	0.260346014817999	0.845000422471102	0	0	2.14981785063752	2.89310384263371	AKAP13;GOSR2
IgE levels	2/18	0.260346014817999	0.845000422471102	0	0	2.14981785063752	2.89310384263371	RAD50;HLA-A
Lead levels in blood	2/18	0.260346014817999	0.845000422471102	0	0	2.14981785063752	2.89310384263371	SEH1L;GBE1
Preeclampsia	2/18	0.260346014817999	0.845000422471102	0	0	2.14981785063752	2.89310384263371	MYCBP2;RUNX1
Retinal vascular caliber	2/18	0.260346014817999	0.845000422471102	0	0	2.14981785063752	2.89310384263371	MTMR9;PTPN11
Sex hormone-binding globulin levels	2/18	0.260346014817999	0.845000422471102	0	0	2.14981785063752	2.89310384263371	FXR2;SAT2
Blond vs. brown/black hair color	11/160	0.265968343477798	0.845000422471102	0	0	1.27116805640296	1.6835069913784	HDAC4;AFG3L1P;NFIA;ZMIZ1;PLK2;DOCK8;ATXN10;TMEM38B;VGLL4;LGR4;MED13L
Alzheimer's disease	4/48	0.270287814827585	0.845000422471102	0	0	1.56403450564035	2.04617614900564	STK24;BIN1;CD33;PICALM
Irritable mood	3/33	0.271840740654942	0.845000422471102	0	0	1.72014585232452	2.2405568802429	ALCAM;ACBD4;TCF4
Urate levels (BMI interaction)	3/33	0.271840740654942	0.845000422471102	0	0	1.72014585232452	2.2405568802429	WIPF1;RFTN1;RNF6
Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	8/112	0.274523995230916	0.845000422471102	0	0	1.32403493941955	1.71160195514119	BLK;EEA1;TNKS;AKTIP;TNFSF13;PPP2R2A;PTPN11;MED13L
Coronary artery disease in type 1 diabetes	2/19	0.28116844757772	0.845000422471102	0	0	2.0232508303868	2.56710334791612	ARL5B;SPNS3
HIV-1 control	2/19	0.28116844757772	0.845000422471102	0	0	2.0232508303868	2.56710334791612	HLA-B;HLA-A
Gout	4/49	0.282711379258606	0.845000422471102	0	0	1.52919708029197	1.93187865587172	KCNQ1;RFX3;PRKCA;ABCG1
Lung function (FEV1/FVC)	6/81	0.286482118659263	0.845000422471102	0	0	1.37659963436929	1.72085851160391	CYFIP2;NR4A2;LST1;DCAF8;CDC7;TMEM38B
Feeling miserable	3/34	0.287060929884013	0.845000422471102	0	0	1.66456905931132	2.07748336935993	KIAA1109;ACBD4;DDB2
Periodontal microbiota	3/34	0.287060929884013	0.845000422471102	0	0	1.66456905931132	2.07748336935993	UHRF2;FOS;RUNX2
Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	NCOR2
Alcohol consumption (drinkers vs non-drinkers)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	OAS3
Blood pressure measurement (low sodium intervention)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	IRAK1BP1
Body mass index  (smoking years interaction)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	PELI2
Bone mineral density (spine) and age at menarche	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	DDX58
Brain volume in infants (white matter)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	WWOX
Cardiac structure and function	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	WWOX
Cerebellum growth	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	TBXAS1
Change in glucose in response to thiazide diuretic treatment in hypertension	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	FARS2
Chronic obstructive pulmonary disease (severe)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	RIN3
Conduct disorder (symptom count)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	SELPLG
Cytomegalovirus antibody response	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	CD53
Depression and alcohol dependence	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	FAF1
Diffusing capacity of the lung for carbon monoxide traits	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	CDH23
EGFR mutation-positive lung adenocarcinoma	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	BPTF
Electrocardiographic conduction measures	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	NFIA
Eye color traits	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	TTC3
Fractional shortening	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	HTATIP2
Gastric adenocarcinoma (histologically verified)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	ATM
Glycemic traits	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	OAS1
Hepatitis B surface antigen seroclearance in chronic hepatitis B infection	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	MPEG1
Hyperopia	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	TOX
Iris color (b* coordinate)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	HK1
Leisure-time exercise behaviour (age-stratified)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	NR4A2
Lobe size	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	EDAR
Memory dysfunction in frontotemporal lobe dementia	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	LRRC37B
Multiple sclerosis and triglyceride levels (pleiotropy)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	NCF4
Osteosarcoma	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	GDI2
Otitis media	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	SERTAD1
Otitis media (chronic)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	SERTAD1
Otitis media (recurrent)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	SERTAD1
Parental lifespan	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	HLA-DRB1
Possible neuropathic pain in post total joint replacement surgery for osteoarthritis	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	PRKCA
Progranulin levels	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	CDH23
Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	CCDC141
Reading and spelling	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	DAZAP1
Remission after SSRI treatment in MDD or openness	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	UTRN
Response to SSRI in MDD or openness	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	UTRN
Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	MAML2
Response to iloperidone treatment (QT prolongation)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	SLCO3A1
Retinal arteriolar caliber	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	MFSD11
Sleep quality	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	SLC2A13
Testicular germ cell cancer	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	CLPTM1L
Type 2 diabetes nephropathy including microalbuminuria	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	TTC39C
White matter lesion progression (adjusted for white matter lesion burden at baseline)	1/6	0.287848854383714	0.845000422471102	0	0	3.4385805277525	4.28213223552626	IRS2
Alzheimer's disease (cognitive decline)	4/50	0.295218183211285	0.845000422471102	0	0	1.49587432561092	1.82502739763922	MAN2A1;SAP30L;CAMK4;ELMO1
Blood osmolality (transformed sodium)	2/20	0.301939875210104	0.845000422471102	0	0	1.91074681238616	2.28817160523315	SLC25A37;KATNAL1
C-reactive protein levels or total cholesterol levels (pleiotropy)	2/20	0.301939875210104	0.845000422471102	0	0	1.91074681238616	2.28817160523315	CARM1;IRF2BP2
Immunoglobulin A	2/20	0.301939875210104	0.845000422471102	0	0	1.91074681238616	2.28817160523315	CLEC16A;HLA-DRB1
Nephropathy	2/20	0.301939875210104	0.845000422471102	0	0	1.91074681238616	2.28817160523315	PSMB8;HLA-DRB1
Post-traumatic stress disorder	2/20	0.301939875210104	0.845000422471102	0	0	1.91074681238616	2.28817160523315	KAT2B;UST
Red vs. brown/black hair color	2/20	0.301939875210104	0.845000422471102	0	0	1.91074681238616	2.28817160523315	AFG3L1P;FANCA
Total bilirubin levels	2/20	0.301939875210104	0.845000422471102	0	0	1.91074681238616	2.28817160523315	AUH;HLA-DRB1
Bone mineral density (spine)	3/35	0.302343866726097	0.845000422471102	0	0	1.61246581586144	1.9288159322395	HDAC5;CCZ1B;AXIN1
Insomnia	3/35	0.302343866726097	0.845000422471102	0	0	1.61246581586144	1.9288159322395	ACBD4;SLC2A13;RFX3
Male-pattern baldness	16/251	0.307337280176387	0.845000422471102	0	0	1.17233257438957	1.38312911071454	SLC35B3;HDAC4;C2ORF42;CLIC4;TIA1;ACBD4;FAF1;ITPR2;LAX1;RUNX1;EDAR;ETAA1;KATNAL1;TCF4;VGLL4;LGR4
Sjogren's syndrome	4/51	0.307792346636478	0.845000422471102	0	0	1.46396956049076	1.72503913892421	BLK;IRAK1BP1;PRCC;HLA-DRB1
Itch intensity from mosquito bite adjusted by bite size	8/117	0.315089523480634	0.845000422471102	0	0	1.26296333635783	1.45859443620289	PINK1;MAPKAP1;IRF1;NCF4;IKZF1;FBXO11;RNF5;SORBS3
Adult asthma	2/21	0.322602964752831	0.845000422471102	0	0	1.81008532259611	2.04780911916518	OAS2;CLEC16A
Phosphorus levels	2/21	0.322602964752831	0.845000422471102	0	0	1.81008532259611	2.04780911916518	LEMD2;ETV6
Response to fenofibrate (LDL cholesterol levels)	2/21	0.322602964752831	0.845000422471102	0	0	1.81008532259611	2.04780911916518	AEBP2;MTHFS
Asthma (sex interaction)	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	IRF1
Childhood and early adolescence aggressive behavior	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	PDSS2
Childhood steroid-sensitive nephrotic syndrome	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	HLA-DRB1
Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	VAC14
Drug-induced liver injury (flucloxacillin)	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	HLA-B
Economic and political preferences (time)	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	THAP2
Emphysema-related traits	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	BICD1
Exploratory eye movement dysfunction in schizophrenia (responsive search score)	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	MAN2A1
Forced expiratory volume in 1 second (occupational environmental exposures interaction)	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	TMEM176A
Hepatitis B vaccine response	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	HLA-DRB1
IgG disialylation phenotypes (multivariate analysis)	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	IKZF1
Influenza A (H1N1) severity	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	MAML2
Lean body mass	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	HSD17B11
Leisure-time exercise behaviour	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	NR4A2
Lifetime average cigarettes per day in chronic obstructive pulmonary disease	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	ELMO1
Lipoprotein (a) - cholesterol levels	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	SNX9
Lung function (forced vital capacity)	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	WWOX
Macular telangiectasia type 2	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	PSPH
Number of children ever born	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	GATAD2B
Perioperative myocardial infarction in coronary artery bypass surgery	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	HDAC4
Plasma androstenedione levels in resected early stage-receptor positive breast cancer	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	ELMO1
Response to antipsychotic therapy (extrapyramidal side effects)	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	TRIM44
Response to antipsychotic treatment in schizophrenia	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	TNIK
Response to bupropion in depression	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	BAZ1A
Response to platinum-based chemotherapy (carboplatin)	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	AKAP13
Staphylococcus aureus infection	1/7	0.3270288634636	0.845000422471102	0	0	2.86533212010919	3.20260132243307	HLA-DRB1
Hemoglobin A1c levels	3/37	0.332990794215485	0.845000422471102	0	0	1.51745401898225	1.66865379658891	KCNQ1;PIEZO1;HK1
Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular)	3/37	0.332990794215485	0.845000422471102	0	0	1.51745401898225	1.66865379658891	IRF1;TYK2;RUNX1
Methadone dose in opioid dependence	3/37	0.332990794215485	0.845000422471102	0	0	1.51745401898225	1.66865379658891	MAML2;STK24;UQCRFS1
Hematocrit	10/153	0.333484624807136	0.845000422471102	0	0	1.20337460704433	1.32149607412784	PXK;NASP;TFR2;DDX58;PRKCE;MICALL2;AP3D1;HLA-A;ATXN10;HK1
Reticulocyte count	11/171	0.340484684774409	0.845000422471102	0	0	1.18308080808081	1.27463367381149	SLC25A37;DNMT1;SMOX;USP3;SWAP70;VPS13A;PIEZO1;BAZ1A;CNNM2;HLA-DRB1;HK1
Glucose homeostasis traits	5/70	0.340920350182542	0.845000422471102	0	0	1.32314717246224	1.4238471485782	SLC35B3;GNA15;KCNQ1;IKZF1;ZZEF1
Ability to confide in someone	2/22	0.343106833240151	0.845000422471102	0	0	1.71948998178506	1.83936149727461	PHF2;TCF4
C-reactive protein levels or LDL-cholesterol levels (pleiotropy)	2/22	0.343106833240151	0.845000422471102	0	0	1.71948998178506	1.83936149727461	CARM1;IRF2BP2
C-reactive protein levels or triglyceride levels (pleiotropy)	2/22	0.343106833240151	0.845000422471102	0	0	1.71948998178506	1.83936149727461	PABPC4;ADAR
Cutaneous malignant melanoma	2/22	0.343106833240151	0.845000422471102	0	0	1.71948998178506	1.83936149727461	KLF4;TMEM38B
Heart rate response to recovery post exercise (30 sec)	2/22	0.343106833240151	0.845000422471102	0	0	1.71948998178506	1.83936149727461	TRIP6;MED13L
Mortality in sepsis	2/22	0.343106833240151	0.845000422471102	0	0	1.71948998178506	1.83936149727461	USP12;VPS13A
Non-glioblastoma glioma	2/22	0.343106833240151	0.845000422471102	0	0	1.71948998178506	1.83936149727461	MAML2;VTI1A
Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	6/87	0.345140134948267	0.845000422471102	0	0	1.27422303473492	1.35552452476861	ZMIZ1;KCNQ1;ITPR2;TMEM38B;CPA5;HLA-DRB1
High light scatter reticulocyte percentage of red cells	11/172	0.347465512371826	0.845000422471102	0	0	1.17566974088713	1.242788566357	BCL2L11;TFR2;SMOX;USP3;SWAP70;PPIF;PIEZO1;TMC8;STRN;BAZ1A;HK1
Alanine transaminase levels	3/38	0.348304632955783	0.845000422471102	0	0	1.47402005469462	1.55461622855063	SERPINA1;ZNF713;STRN
Graves' disease	3/38	0.348304632955783	0.845000422471102	0	0	1.47402005469462	1.55461622855063	FCRL3;HLA-B;CTLA4
Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)	3/38	0.348304632955783	0.845000422471102	0	0	1.47402005469462	1.55461622855063	INPP5D;PITPNA;MLYCD
Cholesterol, total	8/121	0.348339842201198	0.845000422471102	0	0	1.21799734189115	1.28447163895556	MYLIP;LRPAP1;PXK;UBASH3B;ALOX5;IRF2BP2;VIM;TTC39B
Educational attainment	5/71	0.351970208019205	0.845000422471102	0	0	1.3030303030303	1.36063563517648	RILPL2;STK24;RILPL1;IFNGR2;GART
Takayasu arteritis	6/88	0.35505046310348	0.845000422471102	0	0	1.25861684576626	1.30329189125001	FCGR3A;HLA-B;PSMG1;KLF4;CDC73;HLA-DRB1
Hand grip strength	10/156	0.355579387203008	0.845000422471102	0	0	1.17845921829835	1.21853477838713	MLLT10;ADPGK;GBE1;MFAP3;ITPR1;UHRF1BP1;TCF4;HLA-A;HLA-DRB1;BPTF
Serum uric acid levels	4/55	0.35845972350265	0.845000422471102	0	0	1.34886217260627	1.38385027144399	SELENOO;SESTD1;MICALL2;PTGR2
Visceral adipose tissue adjusted for BMI	4/55	0.35845972350265	0.845000422471102	0	0	1.34886217260627	1.38385027144399	TLE1;PDCD6IP;OAS2;HLA-B
Heart rate response to recovery post exercise (40 sec)	2/23	0.363406512545729	0.845000422471102	0	0	1.63752276867031	1.65755491553005	TRIP6;MED13L
IgG glycosylation	2/23	0.363406512545729	0.845000422471102	0	0	1.63752276867031	1.65755491553005	SLC38A10;IKZF1
Osteoarthritis (hip)	2/23	0.363406512545729	0.845000422471102	0	0	1.63752276867031	1.65755491553005	IFRD1;RUNX2
Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	2/23	0.363406512545729	0.845000422471102	0	0	1.63752276867031	1.65755491553005	FTH1;BEST1
Response to metformin (IC50)	2/23	0.363406512545729	0.845000422471102	0	0	1.63752276867031	1.65755491553005	ZNF668;STX4
Western dietary pattern	2/23	0.363406512545729	0.845000422471102	0	0	1.63752276867031	1.65755491553005	EEA1;ITPR1
Beta2-Glycoprotein I plasma levels	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	SLC25A28
Adiposity	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	LRRFIP1
Anticoagulant levels	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	ELMO1
Bipolar disorder lithium response (categorical) or schizophrenia	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	GRAMD1B
Chronic central serous retinopathy	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	PITPNC1
Clopidogrel active metabolite levels	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	VGLL4
Cocaine dependence	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	NCOR2
Diffuse large B cell lymphoma	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	HLA-B
Food allergy (parent-of-origin effect)	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	IQCE
Frontotemporal dementia (age at onset)	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	TNIK
Fuchs's corneal dystrophy	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	TCF4
Hippocampal tail volume (corrected for total hippocampal volume)	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	FAF1
IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis)	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	IKZF1
Lentiform nucleus volume	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	GATAD2B
Mean arterial pressure (alcohol consumption interaction)	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	KAT2B
Metabolite levels (lipid measures)	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	MINK1
Milk allergy	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	ETAA1
Multiple sclerosis (age of onset)	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	RFK
Non-alcoholic fatty liver disease histology (lobular)	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	EHBP1L1
Non-response to selective serotonin reuptake inhibitors and depression	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	MICAL2
Osteoporosis-related phenotypes	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	TBC1D8
Post bronchodilator FEV1/FVC ratio in smoking	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	SERPINA1
Post bronchodilator percent predicted FEV1 in smoking	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	SERPINA1
Renal sinus fat	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	TIAM1
Response to TNF antagonist treatment	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	QKI
Response to tocilizumab in rheumatoid arthritis	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	RCHY1
Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	GRAMD1B
Systemic sclerosis (anti-topoisomerase-positive)	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	IFT122
Total ventricular volume	1/8	0.364055176933749	0.845000422471102	0	0	2.45586897179254	2.48153240432963	MGST3
Stroke	5/73	0.374109667150085	0.845000422471102	0	0	1.26457158205748	1.24333474232988	UBASH3B;IMPA2;WNK1;MICAL2;SMARCA4
Attention deficit hyperactivity disorder	6/90	0.374923548865423	0.845000422471102	0	0	1.22851919561243	1.20521804830724	IFNAR2;PI4K2B;TFEB;TNFRSF10A;CHMP7;TNFRSF10D
Selective IgA deficiency	3/40	0.378798038446901	0.845000422471102	0	0	1.39419547167952	1.35341817639183	FCRL3;CLEC16A;CDH23
Age at voice drop	2/24	0.3834624537991	0.845000422471102	0	0	1.56300712038417	1.49816353022428	NR4A2;TMEM38B
Coronary artery disease or large artery stroke	2/24	0.3834624537991	0.845000422471102	0	0	1.56300712038417	1.49816353022428	CNNM2;SMARCA4
Low tan response	2/24	0.3834624537991	0.845000422471102	0	0	1.56300712038417	1.49816353022428	AFG3L1P;FANCA
Nose morphology	2/24	0.3834624537991	0.845000422471102	0	0	1.56300712038417	1.49816353022428	USP12;MED13L
Blood urea nitrogen levels	4/57	0.38381689730756	0.845000422471102	0	0	1.29782399118579	1.24278284749242	GOSR2;MICALL2;SSBP3;PITPNC1
Longevity	5/74	0.385181129141464	0.845000422471102	0	0	1.24617828072265	1.18890590839645	ABCC4;STK24;NTHL1;SLC38A10;LRRFIP1
Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	7/109	0.392799382951754	0.845000422471102	0	0	1.18029169581831	1.10293097959913	EEA1;TNKS;AKTIP;TNFSF13;PPP2R2A;PTPN11;MED13L
Plateletcrit	14/231	0.39337013362415	0.845000422471102	0	0	1.10990316639933	1.03554442073595	ABCC4;DGKD;TPM4;HLA-B;HLA-A;ARHGAP25;RUNX1;TFR2;IRF1;UHRF1BP1;RIN3;RCOR1;CD33;KDM7A
Childhood ear infection	3/41	0.393935704835805	0.845000422471102	0	0	1.35743415055414	1.26454163129714	HLA-H;HLA-A;HLA-DRB1
Response to methotrexate in juvenile idiopathic arthritis	3/41	0.393935704835805	0.845000422471102	0	0	1.35743415055414	1.26454163129714	TGIF1;CHST11;ZMIZ1
Hypothyroidism	5/75	0.396242065985318	0.845000422471102	0	0	1.22831050228311	1.13708385270938	RPS26;HLA-B;CTLA4;PTPN11;HLA-DRB1
Craniofacial microsomia	4/58	0.39645512447909	0.845000422471102	0	0	1.27372262773723	1.17843852473644	PRPF18;ACBD4;DCAKD;PRKCE
Visceral adipose tissue/subcutaneous adipose tissue ratio	4/58	0.39645512447909	0.845000422471102	0	0	1.27372262773723	1.17843852473644	LRRC47;TMEM38B;TOX;TRAK1
Attention deficit hyperactivity disorder symptom score	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	ARHGEF12
Bipolar disorder lithium response (continuous) or schizophrenia	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	FAM177A1
Bone mineral density (paediatric, lower limb)	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	RIN3
Cardiovascular risk factors (age interaction)	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	SORL1
Cerebrospinal fluid beta-site APP cleaving enzyme levels	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	CDH23
Chronic obstructive pulmonary disease (moderate to severe)	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	RIN3
Diffuse cutaneous systemic sclerosis	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	VAC14
Ear morphology	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	EDAR
Facial morphology	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	MAPRE2
Factor VII	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	MCF2L
Forehead morphology	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	TLE1
High altitude adaptation	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	NEK7
Idiopathic intracranial hypertension	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	FAM8A1
IgG digalactosylation phenotypes (multivariate analysis)	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	IKZF1
IgG monogalactosylation phenotypes (multivariate analysis)	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	IKZF1
Liver transplant-free survival in primary sclerosing cholangitis (time to event)	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	CMC1
Paneth cell defects in Crohn's disease	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	MFSD1
Plasma amyloid beta peptide concentrations (ABx-40)	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	KCNQ1
Response to antipsychotic treatment in schizophrenia (reasoning)	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	WWOX
Response to inhaled corticosteroid treatment in asthma (change in FEV1)	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	TNKS
Serum sulfate level	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	MCOLN2
Social science traits (pleiotropy) (HIPO component 1)	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	TCF4
Susceptibility to persistent hepatitis B virus infection	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	INTS10
Vogt-Koyanagi-Harada syndrome	1/9	0.399046079723933	0.845000422471102	0	0	2.14877161055505	1.97403002374459	HLA-DRB1
Mean arterial pressure	7/110	0.401911718499884	0.845000422471102	0	0	1.16877037458141	1.0653608680066	HDAC4;SWAP70;PABPC4;GOSR2;PTPN11;CNNM2;MED13L
Anger	2/25	0.403240068187255	0.845000422471102	0	0	1.49497109368813	1.35776741820564	PPP1R11;FYN
Antineutrophil cytoplasmic antibody-associated vasculitis	2/25	0.403240068187255	0.845000422471102	0	0	1.49497109368813	1.35776741820564	SERPINA1;KATNAL1
Alopecia areata	6/94	0.414695916865708	0.845000422471102	0	0	1.17242812032574	1.03198267179897	CIITA;KIAA1109;BCL2L11;CLEC16A;CTLA4;DEXI
Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	6/94	0.414695916865708	0.845000422471102	0	0	1.17242812032574	1.03198267179897	TNKS;AKTIP;TNFSF13;PPP2R2A;PTPN11;MED13L
Menopause (age at onset)	6/94	0.414695916865708	0.845000422471102	0	0	1.17242812032574	1.03198267179897	DDX17;APEX1;TLK1;BRCA1;ARHGEF7;SRSF9
Primary biliary cholangitis	7/112	0.420119873329948	0.845000422471102	0	0	1.14638609332113	0.99416344030946	CLEC16A;CISD2;CTLA4;TYK2;DEXI;HLA-DRB1;IL18R1
Carboplatin disposition in epthelial ovarian cancer	2/26	0.422709301825773	0.845000422471102	0	0	1.43260473588342	1.23357377065644	STIM2;PREP
Headache	2/26	0.422709301825773	0.845000422471102	0	0	1.43260473588342	1.23357377065644	NOL4L;BTN2A2
Molybdenum levels	2/26	0.422709301825773	0.845000422471102	0	0	1.43260473588342	1.23357377065644	WWOX;C8ORF31
Optic disc area	2/26	0.422709301825773	0.845000422471102	0	0	1.43260473588342	1.23357377065644	CDC7;VGLL4
Response to fenofibrate (triglyceride levels)	2/26	0.422709301825773	0.845000422471102	0	0	1.43260473588342	1.23357377065644	UTRN;SUMF1
Heel bone mineral density	51/898	0.426267773379767	0.845000422471102	0	0	1.03624073300822	0.883589576165366	PHF2;CLIC4;DOCK8;SRP54;IRS2;PPCDC;COTL1;CTLA4;PIEZO1;LINC01547;SUN2;MAP2K2;DST;MMD;DCAKD;PRKCE;USP3;ARRDC2;AXIN1;ACYP2;BAZ1A;HLA-A;RUNX1;FAM210A;HDAC4;HDAC5;PXK;TXNDC9;SEH1L;PLAG1;ITPR2;BCL2L11;VTI1A;PCNT;MAP4K5;SPAG9;PRELID1;IRF2BP2;KLF4;SORL1;ARHGAP25;ZZEF1;MED13L;NFIA;APC;TBXAS1;ACKR3;TCF4;ATXN10;RAB5A;LGR4
Neutrophil percentage of white cells	7/113	0.429206283847245	0.845000422471102	0	0	1.13551071138808	0.960434975902286	RAD50;IFITM2;BCL2L11;SLC35D1;ZMIZ1;IKZF1;TYK2
Acute graft versus host disease in bone marrow transplantation (recipient effect)	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	WWOX
Acute insulin response	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	ARAP1
Age at smoking initiation in chronic obstructive pulmonary disease	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	CDH23
Amyotrophic lateral sclerosis (age of onset)	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	IFRD1
Complement C3 and C4 levels	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	HLA-A
Depressive symptoms (SSRI exposure interaction)	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	AKTIP
Diastolic blood pressure response to hydrochlorothiazide in hypertension	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	ZDHHC2
Fast beta electroencephalogram	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	TSPYL4
Hip minimal joint space width	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	RUNX2
Idiopathic osteonecrosis of the femoral head	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	ABCG1
IgG sialylation phenotypes (multivariate analysis)	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	IKZF1
Lobe attachment (rater scored)	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	EDAR
Local histogram emphysema pattern	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	RIN3
Midgestational circulating levels of PBDEs (fetal genetic effect)	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	CREBL2
Neonatal lupus	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	LTB
Obsessive-compulsive disorder or autism spectrum disorder	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	IMPA2
Paget's disease	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	RIN3
Parental longevity (mother's attained age)	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	HLA-DRB1
Parkinson disease and lewy body pathology	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	TMEM59
Plasminogen activator inhibitor type 1 levels (PAI-1)	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	TRIP6
Response to selective serotonin reuptake inhibitors in depression	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	PREX1
Seborrheic dermatitis	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	SENP2
Subclinical trait of interstitial lung disease (basilar peel-core ratio of HAA on CT scan)	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	SEH1L
Superior frontal gyrus grey matter volume	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	STIM2
Tourette syndrome	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	PICALM
Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)	1/10	0.432113365946886	0.845000422471102	0	0	1.90991810737034	1.602549837195	PXK
Pulmonary function	4/61	0.434065710366544	0.845000422471102	0	0	1.20649250864387	1.00688960375509	HDAC4;WWOX;AEBP2;PITPNC1
Subcutaneous adipose tissue	4/61	0.434065710366544	0.845000422471102	0	0	1.20649250864387	1.00688960375509	MLLT10;POM121;CTLA4;CDC73
Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	6/96	0.434495485371576	0.845000422471102	0	0	1.14625228519196	0.95548120183837	BLK;TNKS;AKTIP;TNFSF13;PTPN11;MED13L
Alzheimer's disease in APOE e4- carriers	3/44	0.438689181922733	0.849681083520406	0	0	1.2579095982391	1.03647238837398	BIN1;SORL1;PICALM
Angiotensin-converting enzyme inhibitor intolerance	3/44	0.438689181922733	0.849681083520406	0	0	1.2579095982391	1.03647238837398	APC;STIM2;SAP30L
Age at first birth	2/27	0.441844242249935	0.850594887408276	0	0	1.3752276867031	1.12328302066015	NOL4L;GATAD2B
HIV-1 susceptibility	2/27	0.441844242249935	0.850594887408276	0	0	1.3752276867031	1.12328302066015	HLA-B;CD33
Heart rate response to recovery post exercise (50 sec)	2/27	0.441844242249935	0.850594887408276	0	0	1.3752276867031	1.12328302066015	TRIP6;MED13L
Neurociticism	6/97	0.444353037250987	0.85233640771816	0	0	1.13359583743496	0.919500283862631	RFC5;BTN2A2;ACTN1;RPP21;TCF4;DDB2
Eyebrow thickness	5/80	0.451103243725092	0.85233640771816	0	0	1.14611872146119	0.912378173594176	EDAR;CIB2;SNIP1;MANEAL;AGAP3
Urinary albumin excretion	4/63	0.458778008293094	0.85233640771816	0	0	1.16547074106149	0.908121780769318	EFNA3;USP3;ACTN1;TCF4
Cobalt levels	2/28	0.460622754480927	0.85233640771816	0	0	1.32226425669049	1.02498737330436	NFIA;ZMIZ1
Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)	2/28	0.460622754480927	0.85233640771816	0	0	1.32226425669049	1.02498737330436	FTH1;BEST1
Age-related nuclear cataracts	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	MMAB
Conotruncal heart defects	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	SMCHD1
Cortical amyloid beta load	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	HAUS4
Dehydroepiandrosterone sulphate levels	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	BCL2L11
Erythema nodosum in inflammatory bowel disease	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	SOS2
F-cell distribution	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	YTHDC2
Fasting blood insulin	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	UHRF1BP1
Kidney function decline traits	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	CDH23
LDL peak particle diameter (total fat intake interaction)	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	FNBP1
Lateral ventricular volume in normal aging	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	MLLT10
Parent of origin effect on language impairment (paternal)	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	ABCC4
Proinsulin levels	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	ARAP1
Psychosis and Alzheimer's disease	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	BIN1
Pursuit maintenance gain in psychotic disorders	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	UXS1
Radiation response	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	WWOX
Response to alcohol consumption (flushing response)	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	PTPN11
Tonometry	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	PREX1
Virologic severity in Herpes simplex virus type 2 infection	1/11	0.463362694837317	0.85233640771816	0	0	1.71883530482257	1.32220576207133	ARHGAP25
QT interval	7/117	0.465329290780947	0.854301458557298	0	0	1.0939865258255	0.836910601270428	KCNQ1;ELMO1;CLEC16A;TNFRSF17;PRKCA;CCDC141;IER5
Metabolic traits	3/46	0.46781474602619	0.857209679134696	0	0	1.19927497827055	0.911068697293557	IVD;SLC16A10;HPS5
LDL cholesterol levels	4/64	0.470996187641865	0.861379566245026	0	0	1.14598540145985	0.862818458619022	MYLIP;LRPAP1;IRF2BP2;TRAM2
High light scatter reticulocyte count	10/172	0.474886352253989	0.862561944269958	0	0	1.0611620795107	0.790225924799671	BCL2L11;SMOX;USP3;PRKCE;PPIF;PIEZO1;TMC8;HLA-A;BAZ1A;HK1
Fractures	2/29	0.479026144724568	0.862561944269958	0	0	1.27322404371585	0.937093024989878	FAM210A;ETS2
Quantitative traits	2/29	0.479026144724568	0.862561944269958	0	0	1.27322404371585	0.937093024989878	BLOC1S3;FKBP4
Sudden cardiac arrest	2/29	0.479026144724568	0.862561944269958	0	0	1.27322404371585	0.937093024989878	ACYP2;E2F6
Anorexia nervosa	3/47	0.482122762901489	0.862561944269958	0	0	1.1719565757852	0.855008540563746	RPS26;WWOX;VGLL4
Basal cell carcinoma	3/47	0.482122762901489	0.862561944269958	0	0	1.1719565757852	0.855008540563746	CASP10;HLA-B;CLPTM1L
Huntington's disease progression	3/47	0.482122762901489	0.862561944269958	0	0	1.1719565757852	0.855008540563746	PTDSS1;BRF1;CCDC12
Telomere length	3/47	0.482122762901489	0.862561944269958	0	0	1.1719565757852	0.855008540563746	PELI2;CXCR4;ACYP2
Blood and toenail selenium levels	1/12	0.492893927070258	0.862561944269958	0	0	1.56249483001075	1.10540460206052	JMY
Brain volume in infants (grey matter)	1/12	0.492893927070258	0.862561944269958	0	0	1.56249483001075	1.10540460206052	CAAP1
Cannabis dependence symptom count	1/12	0.492893927070258	0.862561944269958	0	0	1.56249483001075	1.10540460206052	PI4K2B
Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction)	1/12	0.492893927070258	0.862561944269958	0	0	1.56249483001075	1.10540460206052	COTL1
Gastric cancer	1/12	0.492893927070258	0.862561944269958	0	0	1.56249483001075	1.10540460206052	ATM
Gastroesophageal reflux disease	1/12	0.492893927070258	0.862561944269958	0	0	1.56249483001075	1.10540460206052	SLCO3A1
IgG N-glycosylation phenotypes (multivariate analysis)	1/12	0.492893927070258	0.862561944269958	0	0	1.56249483001075	1.10540460206052	IKZF1
Ischemic stroke (cardioembolic)	1/12	0.492893927070258	0.862561944269958	0	0	1.56249483001075	1.10540460206052	HK1
Metabolite levels (5-HIAA)	1/12	0.492893927070258	0.862561944269958	0	0	1.56249483001075	1.10540460206052	WWOX
Modified Stumvoll Insulin Sensitivity Index (BMI interaction)	1/12	0.492893927070258	0.862561944269958	0	0	1.56249483001075	1.10540460206052	TOX
Osteoarthritis	1/12	0.492893927070258	0.862561944269958	0	0	1.56249483001075	1.10540460206052	MCF2L
Response to zileuton treatment in asthma (FEV1 change interaction)	1/12	0.492893927070258	0.862561944269958	0	0	1.56249483001075	1.10540460206052	PRKCE
Serum bilirubin levels in metabolic syndrome	1/12	0.492893927070258	0.862561944269958	0	0	1.56249483001075	1.10540460206052	SSBP3
Body mass index	69/1246	0.494872159104087	0.862561944269958	0	0	1.00774627169471	0.708904974067698	SCARB2;KDM5A;FAAH;ADPGK;PHF1;GBE1;IKZF1;APEH;AATF;ETS2;ZDHHC4;RPTOR;HERC4;ALCAM;RPS18;RAC1;UBXN4;TMEM38B;CAST;MAP2K3;AKTIP;SSU72;GTF3A;AXIN1;ARAP1;ATAD3B;ATAD3A;TERF2;LEMD2;ACAP2;OAS1;OAS2;KCNQ1;OAS3;POLR1D;UHRF1BP1;CD47;PABPC1;MTRF1L;VGLL4;SLC27A4;KHDRBS1;INO80D;UBA7;SFSWAP;GOSR2;MAPKAP1;CXCR4;HNRNPLL;TBX21;BLOC1S3;VTI1A;TNFRSF14;BPTF;CDK11A;CCZ1B;XRCC3;ELP3;PTPN11;CDK11B;FAM220A;NASP;WNK1;MFAP3;AVL9;SSBP3;HLA-DRB1;RCOR1;SLC35E2B
Central corneal thickness	4/66	0.49511277342848	0.862561944269958	0	0	1.10890040028255	0.779523400849035	ARL4C;AKAP13;RUNX2;BANP
Severe influenza A (H1N1) infection	3/48	0.496245086143165	0.862561944269958	0	0	1.14585232452142	0.80288193591923	SPRED2;PDCD6IP;PIP4K2A
Microalbuminuria	2/30	0.497038849064077	0.862561944269958	0	0	1.22768670309654	0.858259923237843	PDSS2;CNNM2
Multiple myeloma	2/30	0.497038849064077	0.862561944269958	0	0	1.22768670309654	0.858259923237843	PREX1;DTNBP1
Refractive error	2/30	0.497038849064077	0.862561944269958	0	0	1.22768670309654	0.858259923237843	TOX;CNDP2
Thrombin-activatable fibrinolysis inhibitor activation peptide	2/30	0.497038849064077	0.862561944269958	0	0	1.22768670309654	0.858259923237843	ITPR1;METTL9
Red cell distribution width	13/230	0.500414467154429	0.866838175344011	0	0	1.02967623230555	0.712863996922617	LRRC47;SLC12A2;PABPC4;AXIN1;DONSON;HK1;SLC25A37;CHAF1A;TFR2;EHBP1L1;RAC1;AVL9;FBXO7
Waist circumference adjusted for BMI in active individuals	5/85	0.504555204252725	0.872421816807894	0	0	1.07420091324201	0.734837235405383	ZMIZ1;KCNQ1;ITPR2;TMEM38B;CPA5
Chronic inflammatory diseases (pleiotropy)	10/177	0.511571343439528	0.873513530936814	0	0	1.02911607976707	0.689783807540036	DAP;ZMIZ1;IFNGR2;CMC1;CLEC16A;TNFRSF14;UBASH3A;TYK2;FOS;IL18R1
Waist-to-hip ratio adjusted for BMI (age >50)	14/250	0.511606134113103	0.873513530936814	0	0	1.01950869307363	0.683274949668501	HSP90AB1;ATMIN;SPAG4;ITPR2;IFT122;NCOR2;SLC25A37;RILPL2;RILPL1;CENPN;CNNM2;CHMP7;CPA5;POLH
Bilirubin levels	2/31	0.514648146547265	0.873513530936814	0	0	1.18528986872684	0.787354661172554	DGKD;ARHGEF7
Serum uric acid levels in response to allopurinol in gout	2/31	0.514648146547265	0.873513530936814	0	0	1.18528986872684	0.787354661172554	WWOX;CDK13
Coronary artery disease	24/433	0.514669218795006	0.873513530936814	0	0	1.00840748584361	0.669815389985255	NEK9;NRP1;SERPINA1;ARHGEF12;PRKCE;SWAP70;GOSR2;FBF1;MAP3K7CL;RRP1B;DDX41;ABCC10;TTC39B;SMARCA4;HERPUD1;AKAP13;MCF2L;TBXAS1;EHBP1L1;SPECC1L;MPHOSPH10;UHRF1BP1;RAC1;CNNM2
Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis)	1/13	0.520801442735198	0.873513530936814	0	0	1.43221110100091	0.934355069805233	CTLA4
Barrett's esophagus	1/13	0.520801442735198	0.873513530936814	0	0	1.43221110100091	0.934355069805233	BLK
Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer	1/13	0.520801442735198	0.873513530936814	0	0	1.43221110100091	0.934355069805233	RPUSD4
Lymphoma	1/13	0.520801442735198	0.873513530936814	0	0	1.43221110100091	0.934355069805233	HLA-DRB1
Multiple sclerosis (OCB status)	1/13	0.520801442735198	0.873513530936814	0	0	1.43221110100091	0.934355069805233	HLA-DRB1
Oral cavity cancer	1/13	0.520801442735198	0.873513530936814	0	0	1.43221110100091	0.934355069805233	CLPTM1L
Reading disability or specific language impairment (pleiotropy)	1/13	0.520801442735198	0.873513530936814	0	0	1.43221110100091	0.934355069805233	STK24
Response to anti-TNF therapy in rheumatoid arthritis	1/13	0.520801442735198	0.873513530936814	0	0	1.43221110100091	0.934355069805233	SMARCAL1
Severity of nausea and vomiting of pregnancy	1/13	0.520801442735198	0.873513530936814	0	0	1.43221110100091	0.934355069805233	SPECC1L
Skin pigmentation	1/13	0.520801442735198	0.873513530936814	0	0	1.43221110100091	0.934355069805233	PRPF18
Tenofovir clearance in HIV infection	1/13	0.520801442735198	0.873513530936814	0	0	1.43221110100091	0.934355069805233	KLF4
Wegener's granulomatosis	1/13	0.520801442735198	0.873513530936814	0	0	1.43221110100091	0.934355069805233	RXRB
Neuroticism	8/142	0.523887074349252	0.877141914975596	0	0	1.0259690558198	0.663267577332782	PDCD6IP;TMX2;TRIM39;RPP21;EP300;PRKCA;HLA-E;DDB2
Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes	2/32	0.53184389386558	0.885785539520432	0	0	1.14571948998179	0.723413318512715	PDSS2;ACOT13
Orofacial clefts	2/32	0.53184389386558	0.885785539520432	0	0	1.14571948998179	0.723413318512715	GOSR2;TPM1
Waist-to-hip ratio adjusted for BMI in non-smokers	2/32	0.53184389386558	0.885785539520432	0	0	1.14571948998179	0.723413318512715	RFX7;ITPR2
Basophil percentage of granulocytes	3/51	0.537397783228961	0.885799635199413	0	0	1.07406563354603	0.667012703707902	SLC36A1;RUNX1;CDC25B
Cognitive decline rate in late mild cognitive impairment	7/126	0.544203957144851	0.885799635199413	0	0	1.01076368333244	0.614980141733129	SPRED2;ACTN1;TBC1D8;TMEM38B;SLC15A4;CDC25B;MED13L
Blood trace element (Se levels)	1/14	0.547174441736845	0.885799635199413	0	0	1.32197102260797	0.79713216210782	MREG
Caffeine consumption	1/14	0.547174441736845	0.885799635199413	0	0	1.32197102260797	0.79713216210782	PPCDC
Dimensional psychopathology (Social)	1/14	0.547174441736845	0.885799635199413	0	0	1.32197102260797	0.79713216210782	EIF3B
Early-onset Parkinson's disease	1/14	0.547174441736845	0.885799635199413	0	0	1.32197102260797	0.79713216210782	WWOX
Glycemic traits (pregnancy)	1/14	0.547174441736845	0.885799635199413	0	0	1.32197102260797	0.79713216210782	HK1
Homocysteine levels	1/14	0.547174441736845	0.885799635199413	0	0	1.32197102260797	0.79713216210782	FANCA
Immune reponse to smallpox (secreted IL-1beta)	1/14	0.547174441736845	0.885799635199413	0	0	1.32197102260797	0.79713216210782	EPGN
Immune response to anthrax vaccine	1/14	0.547174441736845	0.885799635199413	0	0	1.32197102260797	0.79713216210782	HLA-DRB1
Immunoglobulin light chain (AL) amyloidosis	1/14	0.547174441736845	0.885799635199413	0	0	1.32197102260797	0.79713216210782	SRP54
Ischemic stroke (large artery atherosclerosis)	1/14	0.547174441736845	0.885799635199413	0	0	1.32197102260797	0.79713216210782	FAF1
Moderate to vigorous physical activity levels	1/14	0.547174441736845	0.885799635199413	0	0	1.32197102260797	0.79713216210782	RPP21
Periodontitis (DPAL)	1/14	0.547174441736845	0.885799635199413	0	0	1.32197102260797	0.79713216210782	TGIF1
Platelet aggregation	1/14	0.547174441736845	0.885799635199413	0	0	1.32197102260797	0.79713216210782	KCNQ1
Systolic blood pressure in sickle cell anemia	1/14	0.547174441736845	0.885799635199413	0	0	1.32197102260797	0.79713216210782	RFX3
Nonsyndromic cleft lip with cleft palate	2/33	0.548618280896377	0.885799635199413	0	0	1.1087020388977	0.665611905788161	RPS26;GOSR2
Self-reported risk-taking behaviour	2/33	0.548618280896377	0.885799635199413	0	0	1.1087020388977	0.665611905788161	CDH23;TCF4
Asthma (childhood onset)	3/52	0.550682227971682	0.887625082713677	0	0	1.05209011590051	0.627674180304892	TLE4;RAD50;IL18R1
Lung cancer in never smokers	2/34	0.564965604937646	0.893373503974177	0	0	1.07399817850638	0.613242677366854	UBR2;CCDC50
Asthma	11/204	0.570862082643379	0.893373503974177	0	0	0.979065264039357	0.548871462210438	BCR;RAD50;IRF1;PREP;CLEC16A;FBXO11;DEXI;HLA-DRB1;IL18R1;CDK5RAP2;ETV6
Atopic march	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	TRAM2
Bone mineral density (paediatric, total body less head)	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	RIN3
Eosinophilic esophagitis	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	SLC25A24
Esophageal cancer	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	RUNX1
Exploratory eye movement dysfunction in schizophrenia (cognitive search score)	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	MAN2A1
Hirschsprung disease	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	STIM2
Idiopathic membranous nephropathy	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	RNF5
Midgestational circulating levels of PCBs	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	SUMF1
Pancreatic ductal adenocarcinoma	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	IGFBP4
Periodontitis (PAL4Q3)	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	CAMK4
Post-traumatic stress disorder (asjusted for relatedness)	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	PRKCA
Sarcoidosis	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	TYK2
Self-rated health	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	TCF4
Smoking initiation	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	SLCO3A1
Sulfasalazine-induced agranulocytosis	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	HLA-B
Thrombosis	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	TSPAN15
Uterine fibroid number (single vs multiple)	1/15	0.572097228097028	0.893373503974177	0	0	1.22747952684258	0.685481428146946	FBXO33
Serum total protein level	3/54	0.57656014238151	0.898866713778386	0	0	1.01072443562658	0.556581306668951	TNFSF13;UBR2;IKZF1
Monocyte count	12/224	0.579445532016854	0.90188658092967	0	0	0.972253052164262	0.53054255724664	IFITM2;BCL2L11;BCL2A1;ARRDC2;HLA-B;GCNT2;CDH23;RIN3;IKZF1;KCNN4;SSBP4;CCR2
Joint mobility (Beighton score)	2/35	0.580882063203461	0.902645166840672	0	0	1.04139758238119	0.565695010616593	TNKS;PIEZO1
Lung cancer	12/225	0.585710428881411	0.90742983781435	0	0	0.967636702568351	0.517617669268845	ETAA1;SPRED2;BTN3A1;ZNF184;WNK1;VTI1A;ADAR;CLPTM1L;DCBLD1;GALK2;HLA-E;BPTF
AIDS progression	1/16	0.595649478057514	0.90742983781435	0	0	1.14558689717925	0.593531903934163	LTB
Alcohol consumption (maxi-drinks)	1/16	0.595649478057514	0.90742983781435	0	0	1.14558689717925	0.593531903934163	PTPN11
BRCA1/2-negative high-risk breast cancer	1/16	0.595649478057514	0.90742983781435	0	0	1.14558689717925	0.593531903934163	ITPR2
Bone mineral density (paediatric, skull)	1/16	0.595649478057514	0.90742983781435	0	0	1.14558689717925	0.593531903934163	LGR4
Cholangiocarcinoma in primary sclerosing cholangitis (time to event)	1/16	0.595649478057514	0.90742983781435	0	0	1.14558689717925	0.593531903934163	MAPKAPK3
Eating disorders (purging via substances)	1/16	0.595649478057514	0.90742983781435	0	0	1.14558689717925	0.593531903934163	PDE6D
Esophageal squamous cell carcinoma	1/16	0.595649478057514	0.90742983781435	0	0	1.14558689717925	0.593531903934163	RUNX1
Lumbar spine bone mineral density (trabecular)	1/16	0.595649478057514	0.90742983781435	0	0	1.14558689717925	0.593531903934163	AXIN1
Non-small cell lung cancer	1/16	0.595649478057514	0.90742983781435	0	0	1.14558689717925	0.593531903934163	NAPG
Palmitic acid (16:0) levels	1/16	0.595649478057514	0.90742983781435	0	0	1.14558689717925	0.593531903934163	SLC15A4
Activated partial thromboplastin time	2/36	0.596365561129305	0.90742983781435	0	0	1.01071466838101	0.522439869884559	PRELID1;LMAN2
Lumbar spine bone mineral density	2/36	0.596365561129305	0.90742983781435	0	0	1.01071466838101	0.522439869884559	AXIN1;ARHGAP25
White blood cell count	12/227	0.598117923097353	0.90864240393863	0	0	0.958532831737346	0.4926545781288	LYN;ETV7;SPRED2;IFITM2;CCDC12;BCL2A1;DOCK8;HLA-B;AK3;RIN3;CD33;SLC25A24
Hippocampal volume	3/56	0.601482196862447	0.911617401757149	0	0	0.972480693486524	0.494368672876989	SCARB2;ACOT4;MED13L
Granulocyte count	7/133	0.601993405156141	0.911617401757149	0	0	0.954254345837146	0.484292467094475	LYN;IFITM2;ZMIZ1;DOCK8;TBC1D8;RIN3;SLC25A24
Lung cancer in ever smokers	8/153	0.609303114109818	0.913886588160612	0	0	0.947581154477706	0.469469048838438	ETAA1;ZNF184;WNK1;HLA-B;HLA-A;CLPTM1L;GALK2;HLA-E
Macular thickness	10/191	0.609327831919513	0.913886588160612	0	0	0.948806325713417	0.470037557180629	WWOX;IRAK1BP1;GTF2A2;MREG;COTL1;FYN;ARHGEF7;FBXO11;SORL1;BPTF
Autism spectrum disorder or schizophrenia	40/752	0.61130171222055	0.913886588160612	0	0	0.963960144159423	0.474427098290152	PPP1R11;PHF1;LST1;ABCC10;RNF5;BAG6;ARL5B;ABHD16A;RPS18;MAN2A1;EP300;CNNM2;HLA-H;HSPA1L;BTN2A2;BTN3A1;ZNF184;ACTR5;HLA-L;XRCC3;HLA-B;NSUN6;HLA-A;HLA-F;PSMB8;DDB2;HLA-E;ATAT1;DDX39B;RILPL2;TRIM39;TMX2;DDAH2;NDUFAF2;RPP21;TSR1;TCF4;LTB;RGL2;HLA-DRB1
Allergy	2/37	0.611415536474609	0.913886588160612	0	0	0.981785063752277	0.483017102281259	CAMK4;CLEC16A
Aspartate aminotransferase levels	2/37	0.611415536474609	0.913886588160612	0	0	0.981785063752277	0.483017102281259	FAM222A;IKZF1
HIV-1 viral setpoint	2/37	0.611415536474609	0.913886588160612	0	0	0.981785063752277	0.483017102281259	HLA-B;SORBS3
Self-reported allergy	2/37	0.611415536474609	0.913886588160612	0	0	0.981785063752277	0.483017102281259	CAMK4;CLEC16A
Cough in response to angiotensin-converting enzyme inhibitor drugs	1/17	0.617906494413537	0.913886588160612	0	0	1.07393084622384	0.517009786729632	SLC38A6
Fat distribution (HIV)	1/17	0.617906494413537	0.913886588160612	0	0	1.07393084622384	0.517009786729632	KATNAL1
P wave duration	1/17	0.617906494413537	0.913886588160612	0	0	1.07393084622384	0.517009786729632	SSBP3
Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid)	1/17	0.617906494413537	0.913886588160612	0	0	1.07393084622384	0.517009786729632	BEST1
QRS interval (sulfonylurea treatment interaction)	1/17	0.617906494413537	0.913886588160612	0	0	1.07393084622384	0.517009786729632	LRRC63
Red blood cell fatty acid levels	1/17	0.617906494413537	0.913886588160612	0	0	1.07393084622384	0.517009786729632	BEST1
Response to statins (LDL cholesterol change)	1/17	0.617906494413537	0.913886588160612	0	0	1.07393084622384	0.517009786729632	MYLIP
Serum folate levels	1/17	0.617906494413537	0.913886588160612	0	0	1.07393084622384	0.517009786729632	KIAA2013
Menarche (age at onset)	11/212	0.622331047283486	0.915139645157469	0	0	0.939695462083522	0.445681674433595	NR4A2;UBA7;DST;TCF7;HLA-A;ARHGEF7;TMEM38B;SSBP3;LGR4;SIRT3;BYSL
Disease progression in age-related macular degeneration	5/97	0.622880399701514	0.915139645157469	0	0	0.933492158030574	0.441915890924391	TLE4;CDH23;UQCRFS1;ACKR3;BAZ1A
Corneal structure	2/38	0.626032797226827	0.915139645157469	0	0	0.954462659380692	0.447024989398151	AKAP13;BANP
Experiencing mood swings	2/38	0.626032797226827	0.915139645157469	0	0	0.954462659380692	0.447024989398151	CHRAC1;TCF4
Heschl's gyrus morphology	2/38	0.626032797226827	0.915139645157469	0	0	0.954462659380692	0.447024989398151	PRKCA;KNSTRN
Blood pressure	5/98	0.631950573643122	0.915139645157469	0	0	0.923405508911474	0.423791504824589	CHIC2;GOSR2;CAMK4;PTPN11;CNNM2
Aggressiveness in attention deficit hyperactivity disorder	1/18	0.638939445869061	0.915139645157469	0	0	1.01070491891024	0.452740814242358	MICAL2
Alzheimer's disease (age of onset)	1/18	0.638939445869061	0.915139645157469	0	0	1.01070491891024	0.452740814242358	LEMD2
Body mass index (adult)	1/18	0.638939445869061	0.915139645157469	0	0	1.01070491891024	0.452740814242358	INTS10
Bone mineral density (Ward's triangle area)	1/18	0.638939445869061	0.915139645157469	0	0	1.01070491891024	0.452740814242358	TNKS
Cardiometabolic and hematological traits	1/18	0.638939445869061	0.915139645157469	0	0	1.01070491891024	0.452740814242358	HLA-B
Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)	1/18	0.638939445869061	0.915139645157469	0	0	1.01070491891024	0.452740814242358	EEA1
Food allergy	1/18	0.638939445869061	0.915139645157469	0	0	1.01070491891024	0.452740814242358	SSBP3
Global electrical heterogeneity phenotypes	1/18	0.638939445869061	0.915139645157469	0	0	1.01070491891024	0.452740814242358	NFIA
Heart rate increase in response to exercise	1/18	0.638939445869061	0.915139645157469	0	0	1.01070491891024	0.452740814242358	TRIP6
Immune response to measles-mumps-rubella vaccine	1/18	0.638939445869061	0.915139645157469	0	0	1.01070491891024	0.452740814242358	CDK8
Influenza A (H1N1) infection	1/18	0.638939445869061	0.915139645157469	0	0	1.01070491891024	0.452740814242358	GHITM
Logical memory (immediate recall) in mild cognitive impairment	1/18	0.638939445869061	0.915139645157469	0	0	1.01070491891024	0.452740814242358	HNRNPL
Peanut allergy	1/18	0.638939445869061	0.915139645157469	0	0	1.01070491891024	0.452740814242358	HLA-DRB1
Staphylococcus aureus nasal carriage (intermittent)	1/18	0.638939445869061	0.915139645157469	0	0	1.01070491891024	0.452740814242358	KAT2B
Iron status biomarkers (transferrin saturation)	2/39	0.640219373052428	0.915139645157469	0	0	0.928617141731896	0.414111605710545	TFR2;GBE1
Nose size	2/39	0.640219373052428	0.915139645157469	0	0	0.928617141731896	0.414111605710545	TNKS;IRS2
Hip circumference adjusted for BMI	5/99	0.640886439195451	0.915139645157469	0	0	0.913533469348101	0.406433780837556	SLC25A37;PLAG1;FAF1;AKTIP;UHRF1BP1
Blood metabolite levels	8/158	0.645396320040647	0.920197751662152	0	0	0.915750915750916	0.400998810629901	SH3GLB2;ABCC4;NASP;IVD;AMD1;SLC16A10;HPS5;PSPH
Squamous cell lung carcinoma	7/139	0.648324763871201	0.922989297068132	0	0	0.910588039590784	0.394615646634105	ZNF184;WNK1;DCAF8;ADAR;HLA-A;CLPTM1L;HLA-E
Nickel levels	2/40	0.653978378461145	0.924090899829216	0	0	0.904131914485668	0.383967635203859	PELI2;SLC38A6
Zinc levels	2/40	0.653978378461145	0.924090899829216	0	0	0.904131914485668	0.383967635203859	CDK19;MICALL2
Blood trace element (Zn levels)	1/19	0.658815594200009	0.924090899829216	0	0	0.954504094631483	0.398325640812082	PPCDC
Cardiac Troponin-T levels	1/19	0.658815594200009	0.924090899829216	0	0	0.954504094631483	0.398325640812082	STARD7
Cerebrospinal AB1-42 levels in mild cognitive impairment	1/19	0.658815594200009	0.924090899829216	0	0	0.954504094631483	0.398325640812082	FRA10AC1
Coronary artery disease or ischemic stroke	1/19	0.658815594200009	0.924090899829216	0	0	0.954504094631483	0.398325640812082	SMARCA4
Feeling tense	1/19	0.658815594200009	0.924090899829216	0	0	0.954504094631483	0.398325640812082	APEH
Heart rate response to recovery post exercise	1/19	0.658815594200009	0.924090899829216	0	0	0.954504094631483	0.398325640812082	MED13L
Initial pursuit acceleration in psychotic disorders	1/19	0.658815594200009	0.924090899829216	0	0	0.954504094631483	0.398325640812082	ARL4C
Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)	1/19	0.658815594200009	0.924090899829216	0	0	0.954504094631483	0.398325640812082	TRAK1
Rosacea symptom severity	7/141	0.663040335398046	0.928647067692992	0	0	0.896901585394164	0.368554308813313	KIAA1109;RAD50;PDCD6IP;EHBP1L1;FANCA;PTGR2;HLA-E
Breast cancer	11/219	0.664681959332516	0.929577269595916	0	0	0.907731157731158	0.370759713595069	MLLT10;ABCC4;ANKRD16;BCL2L11;ZMIZ1;CCDC88C;ITPR1;RIN3;KCNN4;KLF4;SSBP4
Hypertriglyceridemia	2/41	0.667313887868459	0.929864619423708	0	0	0.880902339918733	0.356320369344308	INTS10;HAVCR2
LDL cholesterol	9/181	0.669399743470914	0.929864619423708	0	0	0.898215846353889	0.360520373424932	MYLIP;LRPAP1;PXK;SERPINA1;PRKCE;IRF2BP2;TNIK;RNF130;SMARCA4
Barrett's esophagus  or Esophageal adenocarcinoma	1/20	0.677598508160494	0.929864619423708	0	0	0.904219146592596	0.351922396845944	BLK
Borderline personality disorder	1/20	0.677598508160494	0.929864619423708	0	0	0.904219146592596	0.351922396845944	SNX9
C-reactive protein levels or HDL-cholesterol levels (pleiotropy)	1/20	0.677598508160494	0.929864619423708	0	0	0.904219146592596	0.351922396845944	PABPC4
Carotid intima media thickness	1/20	0.677598508160494	0.929864619423708	0	0	0.904219146592596	0.351922396845944	DLEC1
Cleft lip with or without cleft palate	1/20	0.677598508160494	0.929864619423708	0	0	0.904219146592596	0.351922396845944	GOSR2
Lipid traits (pleiotropy) (HIPO component 1)	1/20	0.677598508160494	0.929864619423708	0	0	0.904219146592596	0.351922396845944	ITPR2
Primary tooth development (time to first tooth eruption)	1/20	0.677598508160494	0.929864619423708	0	0	0.904219146592596	0.351922396845944	RAD51C
Response to angiotensin II receptor blocker therapy	1/20	0.677598508160494	0.929864619423708	0	0	0.904219146592596	0.351922396845944	APBB1IP
Response to hepatitis B vaccine	1/20	0.677598508160494	0.929864619423708	0	0	0.904219146592596	0.351922396845944	OXA1L
Type 2 diabetes (SNP x SNP interaction, 2df)	1/20	0.677598508160494	0.929864619423708	0	0	0.904219146592596	0.351922396845944	FCGR3A
Venous thromboembolism	1/20	0.677598508160494	0.929864619423708	0	0	0.904219146592596	0.351922396845944	TSPAN15
Systemic juvenile idiopathic arthritis	2/42	0.680230820214719	0.93005007024577	0	0	0.858834244080146	0.330928670667315	WWOX;RIN3
Corneal astigmatism	3/63	0.680832686074225	0.93005007024577	0	0	0.858705560619872	0.330119642197022	MAML2;DTNBP1;MED13L
Acne (severe)	11/223	0.687627850134578	0.93005007024577	0	0	0.890413569658853	0.333466562519812	C2ORF42;GUCD1;POLA2;BRD1;TIA1;SELPLG;SART3;TNKS;EHBP1L1;SPECC1L;DDB2
Parkinson's disease	9/184	0.688208421192931	0.93005007024577	0	0	0.882676443629698	0.329824012673143	SCARB2;TIAL1;USP25;ZNF184;SLC2A13;NDUFAF2;CNNM2;CCDC82;SORBS3
Cerebrospinal fluid t-tau:AB1-42 ratio	2/43	0.692734834581018	0.93005007024577	0	0	0.837842640721489	0.307578725339769	RABGAP1L;FBP1
Mild influenza (H1N1) infection	2/43	0.692734834581018	0.93005007024577	0	0	0.837842640721489	0.307578725339769	ESYT2;GHITM
Prostate-specific antigen levels	2/43	0.692734834581018	0.93005007024577	0	0	0.837842640721489	0.307578725339769	CLPTM1L;WDR11
DNA methylation (variation)	1/21	0.695348266349897	0.93005007024577	0	0	0.858962693357598	0.312097614845094	SLCO3A1
Empathy quotient	1/21	0.695348266349897	0.93005007024577	0	0	0.858962693357598	0.312097614845094	GATAD2B
Fasting blood insulin (BMI interaction)	1/21	0.695348266349897	0.93005007024577	0	0	0.858962693357598	0.312097614845094	UHRF1BP1
Free thyroxine concentration	1/21	0.695348266349897	0.93005007024577	0	0	0.858962693357598	0.312097614845094	USP3
Interleukin-6 levels	1/21	0.695348266349897	0.93005007024577	0	0	0.858962693357598	0.312097614845094	CCNYL1
Iron status biomarkers (ferritin levels)	1/21	0.695348266349897	0.93005007024577	0	0	0.858962693357598	0.312097614845094	KCTD17
Iron status biomarkers (iron levels)	1/21	0.695348266349897	0.93005007024577	0	0	0.858962693357598	0.312097614845094	TFR2
Kawasaki disease	1/21	0.695348266349897	0.93005007024577	0	0	0.858962693357598	0.312097614845094	BLK
Narcolepsy	1/21	0.695348266349897	0.93005007024577	0	0	0.858962693357598	0.312097614845094	DNMT1
Type 1 diabetes and autoimmune thyroid diseases	1/21	0.695348266349897	0.93005007024577	0	0	0.858962693357598	0.312097614845094	HSPA1L
Worry too long after an embarrassing experience	1/21	0.695348266349897	0.93005007024577	0	0	0.858962693357598	0.312097614845094	ACBD4
Diastolic blood pressure	33/646	0.696315089395361	0.93005007024577	0	0	0.92263836800592	0.333951731159931	BLK;HDAC4;ZFAND2A;UBE2D3;LFNG;PREX1;UBASH3B;MCF2L;EPC1;CCDC141;CDK17;PRKCE;PLK2;SWAP70;PABPC4;EXOC6B;HLA-B;PTPN11;RRP1B;SENP2;SORBS3;DCBLD1;QKI;ZZEF1;MED13L;NCOR2;SLC25A37;TBCK;AEBP2;SLCO3A1;STIM2;IRF1;TCF4
Prostate cancer	20/399	0.698319527186449	0.931419173007452	0	0	0.904964331085703	0.324953239653057	NAA50;ACTN1;IRS2;ADAR;KLF4;RNF5;ATAT1;EFNA3;BCL2L11;RFX7;PMVK;SIDT1;GEMIN4;UHRF1BP1;ATM;TCF4;CNNM2;MTRF1L;HLA-DRB1;EIF4B
Venous thromboembolism adjusted for sickle cell variant rs77121243-T	4/86	0.703201395710827	0.936616985043412	0	0	0.837546733131565	0.294910211588122	CMTM7;WWOX;RAD50;PRKCE
Resting heart rate	6/127	0.705385903282508	0.937064176676895	0	0	0.851179234592896	0.297070273532212	DDX17;SUN2;WIPF1;MAPKAP1;UBE4B;CCDC141
Alcohol consumption	1/22	0.712121648825601	0.937064176676895	0	0	0.818016378525933	0.277721899761431	OAS3
Asthma and hay fever	1/22	0.712121648825601	0.937064176676895	0	0	0.818016378525933	0.277721899761431	CLEC16A
Pyoderma gangrenosum in inflammatory bowel disease	1/22	0.712121648825601	0.937064176676895	0	0	0.818016378525933	0.277721899761431	KDSR
Response to platinum-based neoadjuvant chemotherapy in cervical cancer	1/22	0.712121648825601	0.937064176676895	0	0	0.818016378525933	0.277721899761431	CALM1
Waist circumference adjusted for body mass index	6/128	0.712482623356307	0.937064176676895	0	0	0.844157401024965	0.286169152473805	ZMIZ1;KCNQ1;ITPR2;TMEM38B;CPA5;HLA-DRB1
Femoral neck bone mineral density	2/45	0.716529875868318	0.937064176676895	0	0	0.798788494937942	0.266264431056019	MYLIP;AXIN1
Lymphocyte percentage of white cells	6/129	0.719461254966767	0.937064176676895	0	0	0.83724974361261	0.275666658321821	IFITM2;ZMIZ1;CMC1;MINK1;ZNF778;RIN3
Logical memory (delayed recall) in normal cognition	3/67	0.720597903499323	0.937064176676895	0	0	0.804865542388332	0.263733503731673	CHST11;NAA35;TERF2
PR interval	3/67	0.720597903499323	0.937064176676895	0	0	0.804865542388332	0.263733503731673	MICAL2;SENP2;MED13L
Pancreatic cancer	6/130	0.726321581108212	0.937064176676895	0	0	0.830453500029486	0.265547815091515	ARL4C;ETAA1;IGFBP4;GTF2H1;CLPTM1L;BICD1
Visceral fat	2/46	0.727835095688178	0.937064176676895	0	0	0.780592813379699	0.247979328630696	LRRC47;TLE1
Waist-to-hip ratio adjusted for BMI in active individuals	2/46	0.727835095688178	0.937064176676895	0	0	0.780592813379699	0.247979328630696	ETAA1;ITPR2
Adolescent idiopathic scoliosis	1/23	0.72797231745636	0.937064176676895	0	0	0.780792455951692	0.247895559073428	TNIK
Blood sugar levels	1/23	0.72797231745636	0.937064176676895	0	0	0.780792455951692	0.247895559073428	KCNQ1
Bone ultrasound measurement (broadband ultrasound attenuation)	1/23	0.72797231745636	0.937064176676895	0	0	0.780792455951692	0.247895559073428	MTMR9
Contrast sensitivity	1/23	0.72797231745636	0.937064176676895	0	0	0.780792455951692	0.247895559073428	INPP5D
Electrocardiographic traits	1/23	0.72797231745636	0.937064176676895	0	0	0.780792455951692	0.247895559073428	KCNQ1
Iron status biomarkers	1/23	0.72797231745636	0.937064176676895	0	0	0.780792455951692	0.247895559073428	TFR2
Metabolite levels (HVA/MHPG ratio)	1/23	0.72797231745636	0.937064176676895	0	0	0.780792455951692	0.247895559073428	RAB10
Non-melanoma skin cancer	1/23	0.72797231745636	0.937064176676895	0	0	0.780792455951692	0.247895559073428	CLPTM1L
Parental longevity (father's attained age)	1/23	0.72797231745636	0.937064176676895	0	0	0.780792455951692	0.247895559073428	TOX
Fibrinogen levels	3/68	0.729913916881032	0.937064176676895	0	0	0.792440922796438	0.24948312484736	ACTN1;PSMG1;ETS2
Systemic sclerosis	3/68	0.729913916881032	0.937064176676895	0	0	0.792440922796438	0.24948312484736	BLK;PXK;HLA-DRB1
Systolic blood pressure	33/657	0.731674045871877	0.937064176676895	0	0	0.905828707375099	0.282999146717557	BLK;RNASEH2B;CLIC4;WIPF1;TNKS;GOSR2;ITPR1;ABCC10;LFNG;SNRNP70;PPP2R5E;MCF2L;CNNM2;RNF130;BANP;ACBD4;SMOX;FEM1B;SWAP70;EXOC6B;HLA-B;PTPN11;RRP1B;SENP2;FBXO33;MED13L;CCT6A;KAT2B;TBCK;DAP;CDC16;CCNYL1;TOX
Testicular germ cell tumor	4/90	0.736390876529987	0.937064176676895	0	0	0.798421320658632	0.244312308436464	RAD51C;MLKL;TNFRSF17;CLPTM1L
Chronic obstructive pulmonary disease	2/47	0.738755630292168	0.937064176676895	0	0	0.763205828779599	0.231089634344196	NOL4L;RIN3
Diabetic retinopathy	2/47	0.738755630292168	0.937064176676895	0	0	0.763205828779599	0.231089634344196	TCF4;UCHL3
Polycystic ovary syndrome	2/47	0.738755630292168	0.937064176676895	0	0	0.763205828779599	0.231089634344196	RAD50;IRF1
Body mass index (age>50)	3/69	0.738983969420304	0.937064176676895	0	0	0.780392806828541	0.236052475248858	AKTIP;BLOC1S3;VTI1A
Body mass index in physically inactive individuals	1/24	0.742950987607129	0.937064176676895	0	0	0.746805396209993	0.221894704185432	TBX21
Cerebrospinal fluid clusterin levels	1/24	0.742950987607129	0.937064176676895	0	0	0.746805396209993	0.221894704185432	DST
Cerebrospinal fluid p-tau levels	1/24	0.742950987607129	0.937064176676895	0	0	0.746805396209993	0.221894704185432	TM2D1
Cerebrospinal fluid t-tau levels in normal cognition	1/24	0.742950987607129	0.937064176676895	0	0	0.746805396209993	0.221894704185432	ETV6
Childhood body mass index	1/24	0.742950987607129	0.937064176676895	0	0	0.746805396209993	0.221894704185432	ELP3
Fasting insulin (dietary factor interaction)	1/24	0.742950987607129	0.937064176676895	0	0	0.746805396209993	0.221894704185432	ARHGEF7
Lumbar spine bone mineral density (integral)	1/24	0.742950987607129	0.937064176676895	0	0	0.746805396209993	0.221894704185432	AXIN1
Obstructive sleep apnea trait (apnea hypopnea index)	1/24	0.742950987607129	0.937064176676895	0	0	0.746805396209993	0.221894704185432	HDAC4
Presence of antiphospholipid antibodies	1/24	0.742950987607129	0.937064176676895	0	0	0.746805396209993	0.221894704185432	SESTD1
Relative hand skill in reading disability	1/24	0.742950987607129	0.937064176676895	0	0	0.746805396209993	0.221894704185432	VGLL4
Body mass index (joint analysis main effects and physical activity interaction)	4/91	0.74423549082311	0.937440995725533	0	0	0.789202114271331	0.233128548034425	ADPGK;TBX21;UHRF1BP1;LEMD2
Sum neutrophil eosinophil counts	6/133	0.746192205115566	0.937458372065949	0	0	0.810706934028128	0.237352342662996	LYN;IFITM2;DOCK8;TBC1D8;RIN3;SLC25A24
Myopia	3/70	0.747810652552209	0.937458372065949	0	0	0.768704336113416	0.223389685926376	NFIA;TNFSF13;TOX
Creatine kinase levels	2/48	0.749299553316806	0.937458372065949	0	0	0.746574800031678	0.2154737592961	BIN1;CNNM2
Pulse pressure	28/567	0.750093755604421	0.937458372065949	0	0	0.889755766621438	0.255855563749465	BLK;KDM5A;VAC14;CHIC2;DAZAP1;WIPF1;FAF1;GOSR2;CEP164;CLEC16A;RP1-130H16.18;RPTOR;ODF2L;MCF2L;DIP2A;PLEKHJ1;BRD1;MAP2K2;UBE2I;PRKCE;SWAP70;TPM1;LIMK1;MED13L;TBCK;DAP;CDC16;RIN3
Cognitive function	4/92	0.751900962773029	0.937458372065949	0	0	0.780192435301924	0.222472389527191	RPS26;RAD51C;ICA1;WRAP53
Alzheimer disease and age of onset	1/25	0.757105589484629	0.937458372065949	0	0	0.71565059144677	0.19913160279781	DST
Alzheimer's disease biomarkers	1/25	0.757105589484629	0.937458372065949	0	0	0.71565059144677	0.19913160279781	CCDC50
Coronary artery calcified atherosclerotic plaque score in type 2 diabetes	1/25	0.757105589484629	0.937458372065949	0	0	0.71565059144677	0.19913160279781	BDP1
Feeling hurt	1/25	0.757105589484629	0.937458372065949	0	0	0.71565059144677	0.19913160279781	ACTN1
Homeostasis model assessment of insulin resistance (dietary factor interaction)	1/25	0.757105589484629	0.937458372065949	0	0	0.71565059144677	0.19913160279781	ARHGEF7
Inflammatory biomarkers	1/25	0.757105589484629	0.937458372065949	0	0	0.71565059144677	0.19913160279781	APBB1IP
Spherical equivalent (joint analysis main effects and education interaction)	1/25	0.757105589484629	0.937458372065949	0	0	0.71565059144677	0.19913160279781	TOX
Thyroid stimulating hormone	1/25	0.757105589484629	0.937458372065949	0	0	0.71565059144677	0.19913160279781	SLC25A37
Allergic rhinitis	5/114	0.758049934930299	0.937458372065949	0	0	0.787189476770977	0.218056222602337	RAD50;SLC35D1;CAMK4;HLA-B;CLEC16A
Breast size	4/93	0.759388586842543	0.937894215697738	0	0	0.771385221028459	0.212317349101716	EPGN;SERPINA1;ELMO1;DCAF8
Basophil percentage of white cells	2/50	0.769291185088011	0.945455266450223	0	0	0.715391621129326	0.187637011392709	SLC36A1;RUNX1
Blood metabolite ratios	2/50	0.769291185088011	0.945455266450223	0	0	0.715391621129326	0.187637011392709	IVD;HPS5
Epithelial ovarian cancer	1/26	0.770481421134514	0.945455266450223	0	0	0.686988171064604	0.179125115218476	MLLT10
Perceived unattractiveness to mosquitoes	1/26	0.770481421134514	0.945455266450223	0	0	0.686988171064604	0.179125115218476	INPP5D
Scalp hair shape	1/26	0.770481421134514	0.945455266450223	0	0	0.686988171064604	0.179125115218476	EDAR
White blood cell count (basophil)	4/95	0.773836260025325	0.948348303201139	0	0	0.75435148792813	0.193411933247569	APBB1IP;IFITM2;HLA-B;RUNX1
Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	20/419	0.77493164070942	0.948468456003421	0	0	0.858674463937622	0.218945208993929	HSP90AB1;ATMIN;GPR68;ADPGK;SPAG4;ITPR2;IFT122;DDX41;NCOR2;SLC25A37;RILPL2;RILPL1;LMAN2;RAB24;CCDC88C;CENPN;ITGA5;CHMP7;CPA5;POLH
Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia	1/27	0.783121292594856	0.953583033620624	0	0	0.660530552250297	0.161478376605119	LST1
Metabolite levels (lipoprotein measures)	1/27	0.783121292594856	0.953583033620624	0	0	0.660530552250297	0.161478376605119	TTC39B
Phospholipid levels (plasma)	1/27	0.783121292594856	0.953583033620624	0	0	0.660530552250297	0.161478376605119	CDK17
Seasonality and depression	1/27	0.783121292594856	0.953583033620624	0	0	0.660530552250297	0.161478376605119	QKI
Glaucoma	2/52	0.78787915304494	0.956391338296017	0	0	0.686703096539162	0.163717269775594	ARHGEF12;TMCO1
Protein quantitative trait loci	2/52	0.78787915304494	0.956391338296017	0	0	0.686703096539162	0.163717269775594	KCNQ1;TMEM38B
Myeloid white cell count	6/140	0.788444594347084	0.956391338296017	0	0	0.768070070124696	0.182564988401105	LYN;IFITM2;DOCK8;TBC1D8;RIN3;SLC25A24
Bladder cancer	1/28	0.795065662720547	0.956811728776542	0	0	0.636032757051865	0.14586175669876	CLPTM1L
Circulating fibroblast growth factor 23 levels	1/28	0.795065662720547	0.956811728776542	0	0	0.636032757051865	0.14586175669876	FAM177A1
Coffee consumption	1/28	0.795065662720547	0.956811728776542	0	0	0.636032757051865	0.14586175669876	OAS2
Leprosy	1/28	0.795065662720547	0.956811728776542	0	0	0.636032757051865	0.14586175669876	IL18R1
Thyroid hormone levels	1/28	0.795065662720547	0.956811728776542	0	0	0.636032757051865	0.14586175669876	NFIA
Vitamin D levels	1/28	0.795065662720547	0.956811728776542	0	0	0.636032757051865	0.14586175669876	COPB1
Glaucoma (primary open-angle)	3/76	0.795833940549153	0.956811728776542	0	0	0.705298385384798	0.161065276971399	DGKD;ARHGEF12;TMCO1
Waist-to-hip ratio adjusted for BMI	17/367	0.800396180180408	0.958551853168251	0	0	0.831948291782087	0.185231996540804	HSP90AB1;GPR68;ADPGK;SPAG4;ITPR2;IFT122;DDX41;NCOR2;SLC25A37;RILPL2;RILPL1;LMAN2;CCDC88C;RAB24;CNNM2;CHMP7;POLH
Pursuit maintenance gain	4/99	0.800670821327075	0.958551853168251	0	0	0.722435651171725	0.160601329085745	SLC35B3;ARHGAP11A;TMEM41B;UXS1
Nasopharyngeal carcinoma (SNP x SNP interaction)	3/77	0.803047887894084	0.958551853168251	0	0	0.695730370297371	0.152602146855052	HLA-B;EPC1;SUMF1
Post bronchodilator FEV1/FVC ratio	9/206	0.804975537514824	0.958551853168251	0	0	0.783182196745872	0.169906200910756	LFNG;WWOX;CHIC2;SERPINA1;PRPF18;SLCO3A1;MSH2;RIN3;TCF4
Depression in smokers	2/54	0.805134687333193	0.958551853168251	0	0	0.660221381532857	0.143100146882779	MICAL1;GALM
Pulmonary function (smoking interaction)	2/54	0.805134687333193	0.958551853168251	0	0	0.660221381532857	0.143100146882779	HDAC4;WWOX
Metabolite levels  (X-11787)	1/29	0.806352768175185	0.958551853168251	0	0	0.613284804367607	0.13199971373505	PRKCE
Monoclonal gammopathy of undetermined significance	1/29	0.806352768175185	0.958551853168251	0	0	0.613284804367607	0.13199971373505	PREX1
Smoking behavior	1/29	0.806352768175185	0.958551853168251	0	0	0.613284804367607	0.13199971373505	ACTN1
Alcohol dependence	2/55	0.81328530833079	0.959743741901912	0	0	0.647730006529883	0.133868496818952	CAST;USP12
Coronary artery calcification	2/55	0.81328530833079	0.959743741901912	0	0	0.647730006529883	0.133868496818952	SLC2A13;PRKCA
Obesity	2/55	0.81328530833079	0.959743741901912	0	0	0.647730006529883	0.133868496818952	RPTOR;WWOX
Adiponectin levels	1/30	0.817018745090536	0.959743741901912	0	0	0.592105676006401	0.119660554828804	WDR11
Bulimia nervosa	1/30	0.817018745090536	0.959743741901912	0	0	0.592105676006401	0.119660554828804	HSD17B11
Glomerular filtration rate in chronic kidney disease	1/30	0.817018745090536	0.959743741901912	0	0	0.592105676006401	0.119660554828804	ALCAM
Pubertal anthropometrics	1/30	0.817018745090536	0.959743741901912	0	0	0.592105676006401	0.119660554828804	TMEM38B
Toenail selenium levels	1/30	0.817018745090536	0.959743741901912	0	0	0.592105676006401	0.119660554828804	JMY
Gut microbiota (functional units)	2/56	0.821129853637477	0.959743741901912	0	0	0.635701275045537	0.125280203774904	DAP;SLC2A6
Pulse pressure x alcohol consumption interaction (2df test)	2/56	0.821129853637477	0.959743741901912	0	0	0.635701275045537	0.125280203774904	TNKS;TRAK1
Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	2/56	0.821129853637477	0.959743741901912	0	0	0.635701275045537	0.125280203774904	ETAA1;ITPR2
Airflow obstruction	1/31	0.827097744732114	0.959743741901912	0	0	0.572338489535942	0.108648388511679	ITPR1
Attention deficit hyperactivity disorder and conduct disorder	1/31	0.827097744732114	0.959743741901912	0	0	0.572338489535942	0.108648388511679	ABHD13
Chronotype	1/31	0.827097744732114	0.959743741901912	0	0	0.572338489535942	0.108648388511679	ACYP2
Fasting blood glucose (BMI interaction)	1/31	0.827097744732114	0.959743741901912	0	0	0.572338489535942	0.108648388511679	ARAP1
Response to amphetamines	1/31	0.827097744732114	0.959743741901912	0	0	0.572338489535942	0.108648388511679	WWOX
Refractive astigmatism	2/57	0.828677299162416	0.959743741901912	0	0	0.624109951978804	0.11728552871087	STIM2;TOX
Post bronchodilator FEV1	5/126	0.829112590266207	0.959743741901912	0	0	0.708668251632137	0.132803947408135	LFNG;SERPINA1;DOCK8;RIN3;YWHAH
Chronic kidney disease	3/81	0.82979063176723	0.959743741901912	0	0	0.659911647149569	0.123127543151421	CST3;LMAN2;RSBN1L
Cognitive ability (MTAG)	3/81	0.82979063176723	0.959743741901912	0	0	0.659911647149569	0.123127543151421	CEP57;SEH1L;IVD
Major depressive disorder	9/212	0.83034613371756	0.959743741901912	0	0	0.759790132431493	0.141254586743773	MYLIP;SLC25A37;ITPRIPL1;FEM1B;RFX3;ITPR2;DVL3;PARP15;UNC13D
Triglyceride levels	4/104	0.830523558419087	0.959743741901912	0	0	0.686131386861314	0.127413901281039	ARL4C;LRPAP1;ADPGK;HERPUD1
Type 2 diabetes	18/397	0.832201534928071	0.959743741901912	0	0	0.812962412028931	0.149325454521978	TLE4;IFNAR2;WWOX;TLE1;TNKS;USP3;FAF1;YTHDC2;HLA-B;ITPR2;CISD2;RNF6;ARAP1;ZZEF1;BCL2L11;ZMIZ1;KCNQ1;TNIK
Cognitive ability	2/58	0.835936560316915	0.959743741901912	0	0	0.612932604735883	0.109839087932047	SEH1L;IVD
Waist-hip ratio	2/58	0.835936560316915	0.959743741901912	0	0	0.612932604735883	0.109839087932047	ETAA1;ITPR2
Dialysis-related mortality	1/32	0.836622042099564	0.959743741901912	0	0	0.553846605418416	0.0987967487217033	RIN3
Motion sickness	1/32	0.836622042099564	0.959743741901912	0	0	0.553846605418416	0.0987967487217033	TLE4
Parental longevity (combined parental attained age, Martingale residuals)	1/32	0.836622042099564	0.959743741901912	0	0	0.553846605418416	0.0987967487217033	HLA-DRB1
Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)	1/32	0.836622042099564	0.959743741901912	0	0	0.553846605418416	0.0987967487217033	ITPR2
Myocardial infarction	2/59	0.842916471384479	0.961945758919817	0	0	0.602147445115521	0.102899417841331	AP3D1;CNNM2
Bipolar disorder	8/194	0.842947653961256	0.961945758919817	0	0	0.737090866123124	0.125932282473047	TBRG1;RBM14;TXNDC9;NFIA;ZMIZ1;IRF2BP2;MRPL11;TTC39B
Intraocular pressure	18/401	0.843736458929084	0.961945758919817	0	0	0.804298200315632	0.136662397555217	PTPN1;ARHGEF12;FANCA;ICA1;TBC1D8;TRAM2;RUNX2;ETS2;TMCO1;AKAP13;SPRED2;ODF2L;ALCAM;FYN;TCF4;SOS2;TRMT61B;BANP
Hematological and biochemical traits	1/33	0.845622139281774	0.961945758919817	0	0	0.536510464058235	0.0899635033545846	PRKCE
Loneliness (multivariate analysis)	1/33	0.845622139281774	0.961945758919817	0	0	0.536510464058235	0.0899635033545846	UTRN
Pelvic organ prolapse	1/33	0.845622139281774	0.961945758919817	0	0	0.536510464058235	0.0899635033545846	MAML2
Social communication problems	1/33	0.845622139281774	0.961945758919817	0	0	0.536510464058235	0.0899635033545846	RNF111
Waist-to-hip ratio adjusted for BMI (age <50)	6/153	0.852351104897208	0.962869364496861	0	0	0.699660485766519	0.111775479775761	SLC25A37;LMAN2;RAB24;DDX41;CHMP7;POLH
Immune reponse to smallpox (secreted IFN-alpha)	1/34	0.854126862240898	0.962869364496861	0	0	0.520224997932004	0.0820267603799159	WDR92
Initial alcohol sensitivity	1/34	0.854126862240898	0.962869364496861	0	0	0.520224997932004	0.0820267603799159	PIGG
Serum metabolite concentrations in chronic kidney disease	1/34	0.854126862240898	0.962869364496861	0	0	0.520224997932004	0.0820267603799159	TMEM176A
Diisocyanate-induced asthma	11/261	0.855647027307554	0.962869364496861	0	0	0.753535353535354	0.117474156576727	MYLIP;PRKCE;SMPD1;GLRX5;CDH23;IFT122;ASAP1;E2F6;QKI;PITPNC1;HERPUD1
Advanced age-related macular degeneration	2/61	0.856073069501069	0.962869364496861	0	0	0.581673921768392	0.0903918627327885	GPX4;TNFRSF10A
Calcium levels	2/61	0.856073069501069	0.962869364496861	0	0	0.581673921768392	0.0903918627327885	DGKD;ITPR1
Hair color	2/61	0.856073069501069	0.962869364496861	0	0	0.581673921768392	0.0903918627327885	PIEZO1;RNF166
Hippocampal volume in Alzheimer's disease dementia	2/61	0.856073069501069	0.962869364496861	0	0	0.581673921768392	0.0903918627327885	VAC14;CEP164
Body mass index x sex x age interaction (4df test)	4/109	0.856558866839478	0.962869364496861	0	0	0.653284671532847	0.101149525166136	AKTIP;BLOC1S3;VTI1A;IKZF1
Mercury levels	1/35	0.862163453523025	0.967414658872455	0	0	0.504897500401434	0.0748815527871462	TOX
Metabolite levels	4/111	0.865977943257459	0.967414658872455	0	0	0.641005525615663	0.0922380288246809	SERPINA1;TNKS;SLC16A10;RNF111
Waist-to-hip ratio adjusted for body mass index	4/111	0.865977943257459	0.967414658872455	0	0	0.641005525615663	0.0922380288246809	ETAA1;RFX7;ITPR2;SLC38A6
Brown vs. black hair color	1/36	0.869757658607728	0.967414658872455	0	0	0.490445859872611	0.068437138716611	ZMIZ1
Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging)	1/36	0.869757658607728	0.967414658872455	0	0	0.490445859872611	0.068437138716611	PRKCE
Chronic obstructive pulmonary disease-related biomarkers	1/36	0.869757658607728	0.967414658872455	0	0	0.490445859872611	0.068437138716611	PELI2
Gestational age at birth (maternal effect)	1/36	0.869757658607728	0.967414658872455	0	0	0.490445859872611	0.068437138716611	CDC7
Heart rate	1/36	0.869757658607728	0.967414658872455	0	0	0.490445859872611	0.068437138716611	CCDC141
Logical memory (immediate recall) in normal cognition	1/36	0.869757658607728	0.967414658872455	0	0	0.490445859872611	0.068437138716611	PI4K2B
Axial length	2/64	0.873927211000751	0.969725641474428	0	0	0.553440272636465	0.0745806090829865	PEX16;SNIP1
Feeling nervous	1/37	0.876933808273405	0.969725641474428	0	0	0.476797088262056	0.0626147885957701	NFIA
Glomerular filtration rate in non diabetics (creatinine)	1/37	0.876933808273405	0.969725641474428	0	0	0.476797088262056	0.0626147885957701	KCNQ1
Lipid metabolism phenotypes	1/37	0.876933808273405	0.969725641474428	0	0	0.476797088262056	0.0626147885957701	PPP1R11
Smooth-surface caries	1/37	0.876933808273405	0.969725641474428	0	0	0.476797088262056	0.0626147885957701	ITPR2
Reaction time	2/65	0.879409995496176	0.971334385269295	0	0	0.544626593806922	0.0699867263270346	APC;PTPN11
Urate levels in lean individuals	1/38	0.883714896312023	0.971756526995852	0	0	0.46388608808991	0.0573459618258262	IQCE
Vertical cup-disc ratio	1/38	0.883714896312023	0.971756526995852	0	0	0.46388608808991	0.0573459618258262	CDC7
Cognitive performance	4/116	0.887230160531746	0.971756526995852	0	0	0.612226277372263	0.0732533934604045	NCOR2;NIN;TOX;MAP4K5
Sum basophil neutrophil counts	5/140	0.889531438104849	0.971756526995852	0	0	0.634703196347032	0.074298628408619	LYN;IFITM2;DOCK8;RIN3;SLC25A24
Copper levels	2/67	0.889720153987744	0.971756526995852	0	0	0.527812806501331	0.0616740288529578	CMTM7;FARS2
Ischemic stroke	2/67	0.889720153987744	0.971756526995852	0	0	0.527812806501331	0.0616740288529578	SWAP70;SMARCA4
Lung function (FEV1)	2/67	0.889720153987744	0.971756526995852	0	0	0.527812806501331	0.0616740288529578	NCOR2;RPUSD4
Lung function (FVC)	2/67	0.889720153987744	0.971756526995852	0	0	0.527812806501331	0.0616740288529578	EDAR;MED13L
Endometrial cancer (endometrioid histology)	1/39	0.890122652934821	0.971756526995852	0	0	0.451654614242613	0.0525707965608568	BPTF
Fasting blood glucose	1/39	0.890122652934821	0.971756526995852	0	0	0.451654614242613	0.0525707965608568	ARAP1
Neutrophil count	7/187	0.894630617593482	0.971756526995852	0	0	0.666056724611162	0.0741616621708525	LYN;FAM222A;IFITM2;DOCK8;HLA-B;RIN3;SLC25A24
Body mass index x age interaction	1/40	0.896177614032179	0.971756526995852	0	0	0.440050395464408	0.0482368526927078	BLOC1S3
Erosive tooth wear (severe vs non-severe)	1/40	0.896177614032179	0.971756526995852	0	0	0.440050395464408	0.0482368526927078	CEP57
Post bronchodilator FEV1 in COPD	1/40	0.896177614032179	0.971756526995852	0	0	0.440050395464408	0.0482368526927078	ASAP1
Serum albumin level	1/40	0.896177614032179	0.971756526995852	0	0	0.440050395464408	0.0482368526927078	HLA-B
Tourette's syndrome or obsessive-compulsive disorder	1/40	0.896177614032179	0.971756526995852	0	0	0.440050395464408	0.0482368526927078	MYCBP2
Depression	2/69	0.899206880921503	0.971756526995852	0	0	0.512002827393089	0.0543962799603505	NR4A2;TCF4
Hip circumference	2/69	0.899206880921503	0.971756526995852	0	0	0.512002827393089	0.0543962799603505	FAF1;UHRF1BP1
Idiopathic dilated cardiomyopathy	2/69	0.899206880921503	0.971756526995852	0	0	0.512002827393089	0.0543962799603505	WWOX;UBE2I
Liver enzyme levels (gamma-glutamyl transferase)	1/41	0.90189918706514	0.973559735413108	0	0	0.429026387625114	0.0442980604605724	DENND2D
Diastolic blood pressure x alcohol consumption interaction (2df test)	3/96	0.904037928502546	0.974237703652297	0	0	0.553033199047255	0.055792180880033	IRAK1BP1;TNKS;KIAA2013
Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)	1/42	0.907305712460161	0.974237703652297	0	0	0.418540136265785	0.0407138377694421	KIAA2013
Lipoprotein (a) levels	1/42	0.907305712460161	0.974237703652297	0	0	0.418540136265785	0.0407138377694421	SCAF8
Morning vs. evening chronotype	1/42	0.907305712460161	0.974237703652297	0	0	0.418540136265785	0.0407138377694421	ACYP2
Creatinine levels	3/97	0.907754280381582	0.974237703652297	0	0	0.547120774258616	0.0529511983885186	TFEB;MICALL2;HLA-DRB1
Familial squamous cell lung carcinoma	1/43	0.912414522852553	0.974237703652297	0	0	0.408553230209281	0.0374483451348687	WWOX
Urate levels in overweight individuals	1/43	0.912414522852553	0.974237703652297	0	0	0.408553230209281	0.0374483451348687	MED13L
Clozapine-induced agranulocytosis	2/73	0.915939049166676	0.974237703652297	0	0	0.48305497832166	0.042414862998662	RFX7;HLA-B
Atrial fibrillation	9/240	0.916433003022598	0.974237703652297	0	0	0.666694442129823	0.0581799673804334	FXR2;WIPF1;FAF1;USP3;GOSR2;PMVK;UST;UBE4B;SORL1
Serum metabolite levels	3/100	0.918133245540595	0.974237703652297	0	0	0.530114933887171	0.0452785749803401	GTF2H1;HPS5;RABGGTB
Daytime sleep phenotypes	10/263	0.918300554902047	0.974237703652297	0	0	0.676179424883055	0.0576311375817834	CYFIP2;WWOX;GCLC;DST;GPR68;SLC2A13;CCDC88C;PSMG1;RTN4IP1;RABGGTB
Cerebrospinal AB1-42 levels in normal cognition	2/74	0.919694457120901	0.974237703652297	0	0	0.47632058287796	0.0398745945437511	UBR4;RUNX2
Chin dimples	2/74	0.919694457120901	0.974237703652297	0	0	0.47632058287796	0.0398745945437511	TNFSF13;TCF4
Migraine	2/74	0.919694457120901	0.974237703652297	0	0	0.47632058287796	0.0398745945437511	NRP1;NLRP1
Urate levels	2/74	0.919694457120901	0.974237703652297	0	0	0.47632058287796	0.0398745945437511	ADPGK;PTPN11
Endometrial cancer	1/45	0.921803617355436	0.974237703652297	0	0	0.389941268922161	0.0317502169796185	BPTF
Metabolic syndrome	1/45	0.921803617355436	0.974237703652297	0	0	0.389941268922161	0.0317502169796185	HERPUD1
Dental caries	2/75	0.923291535951521	0.974237703652297	0	0	0.469770691419018	0.0374925104132428	ACAD9;SIDT1
Waist circumference	2/75	0.923291535951521	0.974237703652297	0	0	0.469770691419018	0.0374925104132428	GBE1;UHRF1BP1
Monobrow	2/76	0.926736321601974	0.974237703652297	0	0	0.463397824053562	0.0352581779422178	EDAR;TTC32
BMI (adjusted for smoking behaviour)	2/77	0.930034665747227	0.974237703652297	0	0	0.457194899817851	0.0331619090194182	SCARB2;ADPGK
Body mass index (joint analysis main effects and smoking interaction)	2/77	0.930034665747227	0.974237703652297	0	0	0.457194899817851	0.0331619090194182	SCARB2;ADPGK
Coronary heart disease	2/77	0.930034665747227	0.974237703652297	0	0	0.457194899817851	0.0331619090194182	TTC32;CNNM2
Intracranial aneurysm	1/47	0.930186997808923	0.974237703652297	0	0	0.372947739051311	0.0269900936641052	CNNM2
Pelvic organ prolapse (moderate/severe)	1/47	0.930186997808923	0.974237703652297	0	0	0.372947739051311	0.0269900936641052	BIN1
Prudent dietary pattern	1/47	0.930186997808923	0.974237703652297	0	0	0.372947739051311	0.0269900936641052	CDC16
Urate levels in obese individuals	1/47	0.930186997808923	0.974237703652297	0	0	0.372947739051311	0.0269900936641052	LGR4
Cerebrospinal P-tau181p levels	1/48	0.934035647299577	0.977192409881075	0	0	0.364993320813893	0.0249073906587398	MTHFS
Endometriosis	1/49	0.937672303689086	0.97948393412672	0	0	0.3573703366697	0.0229984777529592	ETAA1
Body mass index in physically active individuals	2/80	0.939106844804113	0.97948393412672	0	0	0.43954042314698	0.027614575640969	ADPGK;UHRF1BP1
Amyotrophic lateral sclerosis (sporadic)	6/182	0.939315823263479	0.97948393412672	0	0	0.583471829815523	0.0365273882199927	ALCAM;GLRX5;TBXAS1;CXCR4;FYN;ABCG1
Delirium	1/50	0.941108633714478	0.98027854398956	0	0	0.350058494735474	0.0212473958198323	IL18R1
Initial pursuit acceleration	1/51	0.944355663165266	0.98258450292141	0	0	0.343039126478617	0.0196398208199809	ALCAM
Body mass index (age <50)	1/53	0.950322923736107	0.98740284729974	0	0	0.329810317071464	0.0168049677039529	IKZF1
Amyotrophic lateral sclerosis	1/54	0.953062305765537	0.98740284729974	0	0	0.323570312634127	0.0155556424263102	ITPR2
Bone mineral density (hip)	1/54	0.953062305765537	0.98740284729974	0	0	0.323570312634127	0.0155556424263102	HDAC5
Dupuytren's disease	1/56	0.958096566299027	0.98740284729974	0	0	0.311771031516254	0.0133458909467411	MAP4K5
Sleep duration	1/56	0.958096566299027	0.98740284729974	0	0	0.311771031516254	0.0133458909467411	MAPKAP1
Type 2 diabetes (age of onset)	1/56	0.958096566299027	0.98740284729974	0	0	0.311771031516254	0.0133458909467411	PLK2
Obesity-related traits	34/804	0.958979442035167	0.98740284729974	0	0	0.750980726590483	0.0314553092660291	ARHGAP11A;C2ORF42;ANKRD16;DOCK8;ICA1;ITPR1;CLEC16A;UBR2;AATF;BICD1;PTDSS1;CHST11;RSBN1L;TRAPPC12;PIP4K2A;PHACTR2;CCR2;HTATIP2;CD53;RFC5;MMD;GLRX5;IFNGR2;IL10RA;SPNS3;LEMD2;WDR11;SLCO3A1;UBXN11;AEBP2;STIM2;TBXAS1;BDP1;FBP1
Bone mineral density	2/89	0.96008177478199	0.98740284729974	0	0	0.393882293825765	0.0160455105621147	AXIN1;LGR4
Diastolic blood pressure (cigarette smoking interaction)	1/57	0.960407606469253	0.98740284729974	0	0	0.306187443130118	0.0123692055684876	BLK
Epstein-Barr virus copy number in lymphoblastoid cell lines	1/57	0.960407606469253	0.98740284729974	0	0	0.306187443130118	0.0123692055684876	WWOX
Verbal declarative memory	1/57	0.960407606469253	0.98740284729974	0	0	0.306187443130118	0.0123692055684876	ZBP1
BMI in non-smokers	1/58	0.962591291020535	0.988579176847223	0	0	0.300799770125952	0.0114684031826679	ADPGK
Thiazide-induced adverse metabolic effects in hypertensive patients	1/60	0.966604256221765	0.9904030359274	0	0	0.290572323067195	0.00986961331570573	ZDHHC20
Intelligence (MTAG)	13/366	0.968096476867966	0.9904030359274	0	0	0.62836614014193	0.0203738487012552	CEP57;PHF2;SEH1L;GPX1;BTN3A1;BTN2A2;RBL2;PREX1;CLN3;MAN2A1;IVD;NDUFAF2;AVL9
Hypertension	1/61	0.968446425129922	0.9904030359274	0	0	0.285714285714286	0.0091606042949403	MED13L
Coronary artery disease (myocardial infarction, PTCA, CABG, angina or CIHD)	2/94	0.968532937342252	0.9904030359274	0	0	0.372376653203453	0.0119059198261817	SWAP70;CNNM2
Systolic blood pressure (cigarette smoking interaction)	1/66	0.976241523432616	0.995540438276288	0	0	0.263666270035697	0.00633992418747107	BLK
Age-related macular degeneration	1/67	0.977552436736195	0.995540438276288	0	0	0.259657539912317	0.00589509466932411	TNFRSF10A
Response to statin therapy	2/102	0.978586180091361	0.995540438276288	0	0	0.342440801457195	0.00741261821783226	NR4A2;CDK5RAP2
Ovarian cancer	1/68	0.978791072332628	0.995540438276288	0	0	0.25576847337471	0.00548292628093137	MLLT10
Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)	1/68	0.978791072332628	0.995540438276288	0	0	0.25576847337471	0.00548292628093137	ITPR2
Waist circumference adjusted for BMI in non-smokers	1/69	0.979961411942776	0.995665921749551	0	0	0.251993791147032	0.00510087940253994	TMEM38B
Birth weight	1/72	0.98309925449797	0.996146491327673	0	0	0.241307718925015	0.00411313662388575	ITPR2
Prostate cancer (SNP x SNP interaction)	1/74	0.984913340625892	0.996146491327673	0	0	0.234671619280292	0.00356738895484412	UPF2
Glomerular filtration rate	2/111	0.986189174270966	0.996146491327673	0	0	0.314015474340335	0.00436703909755146	MICALL2;HLA-DRB1
Alcoholic chronic pancreatitis	3/145	0.987941141578029	0.996146491327673	0	0	0.361254124565075	0.00438279150700699	DDI2;PLEKHM2;TTC39B
Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)	1/79	0.988642217738505	0.996146491327673	0	0	0.219570238678519	0.0025081013124633	TMEM38B
Systolic blood pressure x alcohol consumption interaction (2df test)	2/115	0.98865431912083	0.996146491327673	0	0	0.302835404677854	0.00345551371757919	TNKS;KIAA2013
Glomerular filtration rate (creatinine)	1/81	0.989861655420243	0.996146491327673	0	0	0.214058234758872	0.00218127216756432	KCNQ1
Mean arterial pressure x alcohol consumption interaction (2df test)	1/81	0.989861655420243	0.996146491327673	0	0	0.214058234758872	0.00218127216756432	KIAA2013
Waist circumference adjusted for BMI (adjusted for smoking behaviour)	1/81	0.989861655420243	0.996146491327673	0	0	0.214058234758872	0.00218127216756432	TMEM38B
Schizophrenia	34/882	0.991038443855691	0.996276490599114	0	0	0.678970937024319	0.0061120640641924	NRP1;GRAMD1B;BTG1;TNKS;CISD2;PPP2R2A;ZDHHC2;ETS2;DCAF6;BAG6;LMBR1;MAN2A1;EP300;FYN;CNNM2;BRD1;TLE1;BTN2A2;BTN3A1;ZNF184;ACTR5;XRCC3;HLA-B;NSUN6;FBXO11;LEMD2;ARHGAP31;RILPL2;TMX2;IRF3;TSR1;SRSF4;TCF4;HLA-DRB1
Blood protein levels	89/2091	0.997190758472381	0.999922295472941	0	0	0.743036389920663	0.00209030614714494	NRP1;SIGLEC9;SERPINA1;PPP1R11;ZFAND4;CCDC126;UXS1;RP11-673E1.1;LST1;GDI2;PREP;SPINT2;APEH;NAGPA;CYB5D2;LMNB1;FCGR3A;ALCAM;UBASH3B;ABHD16A;ADGRE5;SMPD1;PDE4A;ARFIP1;FBXO7;PGM1;CD33;CCR2;HAVCR2;CAST;GPX1;DDX58;CD300A;FCRL3;SWAP70;HLA-L;HLA-B;PRKCA;ACYP2;HLA-A;PTGR2;EDAR;DDX39B;MAPKAPK3;OAS1;BIN1;PPIF;RPP21;LTB;MTRF1L;SIDT2;LRPAP1;INO80D;SELPLG;CLEC12A;TAPBPL;CST7;LILRA5;BAG6;CST3;NT5C;CHST11;LMAN2;PSMB1;FAM177A1;CDH23;TNFRSF17;LTA4H;RELT;CYB5A;CD72;HSPA1L;SPAG4;MTHFS;GTF2H1;KIAA2013;HPS5;HNRNPAB;ARHGAP25;PSMB8;MAPK13;ATAT1;TRIM39;NASP;WNK1;UST;CHPT1;HLA-DRB1;IL18R1
General cognitive ability	7/299	0.997677900354774	0.999922295472941	0	0	0.408126433468273	0.000948812291547336	RBL2;PREX1;CLN3;BTN3A1;BTN2A2;HLA-L;GATAD2B
Triglycerides	2/184	0.999657534146001	0.999922295472941	0	0	0.187333613563122	6.41663539713974e-05	LRPAP1;ACACB
Spherical equivalent or myopia (age of diagnosis)	2/191	0.999761269283778	0.999922295472941	0	0	0.180327868852459	4.30549407588128e-05	USP25;CCZ1B
Night sleep phenotypes	13/555	0.999922295472941	0.999922295472941	0	0	0.40507914738761	3.14777065653499e-05	SRXN1;MMD;KDM8;RFTN1;ROGDI;GTF3A;NSMCE1;ICA1;NR2F6;FAM107B;ETV6;TBCK;TNIK
